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[57] ABSTRACT 
A novel class of tetrapeptide a-ketoarnides useful for selec-
tively inhibiting serine proteases. selectively inhibiting cys-
teine proteases, generally inhibiting all serine proteases. and 
generally inhibiting all cysteine proteases. having the for-
mula M 1-AA1-AA2-AA3-AA4--CO-NR3R4 • 
4 Claims, No Drawings 
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TETRAPEPTIDE a-KETOAMIDES 
This is a continuation-in-part of application Ser. No. 
08/539,944 filed on Oct. 6. 1995. now U.S. Pat. No. 5.650. 
508. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to a novel class of peptide ketoa-
mides useful for selectively inhibiting serine proteases, 
selectively inhibiting cysteine proteases. generally inhibit-
ing all serine proteases. and generally inhibiting all cysteine 
proteases. Serine proteases and cysteine proteases are 
involved in numerous disease states and inhibitors for these 
enzymes can be used therapeutically for the treatment of 
diseases involving serine proteases or cysteine proteases. We 
have discovered that peptide a-ketoamides can be con-
structed to inhibit selectively individual serine or cysteine 
proteases or groups of serine or cysteine proteases. We have 
found that peptide ketoamides which contain hydrophobic 
aromatic amino acid residues in the P 1 site are potent 
inhibitors of chymases and chymotrypsin-like enzymes. 
Ketoamides containing small hydrophobic amino acid resi-
dues at the P 1 position are good inhibitors of elastases. 
Inhibitors of elastases and chymases are useful as anti-
infiammatory agents. We show that peptide ketoamides 
which contain cationic amino acid residues such as Arg and 
Lys in the P 1 site will be potent inhibitors of trypsin and 
blood coagulation enzymes. These inhibitors are thus useful 
as anticoagulants. Cysteine proteases such as papain, cathe-
psin B. and calpain I and Il are also inhibited by ketoamides. 
Ketoamides with aromatic amino acid residues in the P 1 site 
are good inhibitors for cathepsin B and papain. Thus, they 
would have utility as anticancer agents. Ketoamides with 
either aromatic amino acid residues or small hydrophobic 
alkyl amino acid residues at P1 are good inhibitors of calpain 
I and II. These inhibitors are useful as neuroprotectants and 
can be used as therapeutics for the treatment of neurode-
generation and stroke. 
2. Nomenclature 
In discussing the interactions of peptides with serine and 
cysteine proteases. we have utilized the nomenclature of 
Schechter and Berger [ Biochem. Biophys. Res. Commun. 27. 
157-162 (1%7); inc01p0rated herein by reference]. The 
individual amino acid residues of a substrate or inhibitor are 
designated P 1, P 2 • etc. and the corresponding subsites of the 
enzyme are designated S1• S2• etc. The scissile bond of the 
substrate is S1-S1'. The primary substrate recognition site of 
serine proteases is S 1. The most important recognition 
subsites of cysteine proteases are S1 and S2• 
2 
3. Description of the Related Art 
Cysteine Proteases. Cysteine proteases such as calpain 
use a cysteine residue in their catalytic mechanism in 
contrast to serine proteases which utilize a serine residue. 
5 Cysteine proteases include papain. cathepsin B. calpains. 
and several viral enzymes. Neural tissues. including brain, 
are known to possess a large variety of proteases. including 
at least two calcium stimulated proteases termed calpains. 
Calpains are present in many tissues in addition to the brain. 
10 Calpain I is activated by micromolar concentrations of 
calcium while calpain II is activated by millimolar concen-
trations. In the brain, calpain II is the predominant form, but 
calpain I is found at synaptic endings and is thought to be the 
form involved in long term potentiation, synaptic plasticity. 
15 and cell death. Other Ca2+ activated cysteine proteases may 
exist, and the term "calpain" is used to refer to all ea2+ 
activated cysteine proteases. including calpain I and calpain 
II. The terms "calpain f' and "calpain II" are used herein to 
refer to the micromolar and millimolar activated calpains. 
20 respectively. as described above. While calpains degrade a 
wide variety of protein substrates. cytoskeletal proteins 
seem to be particularly susceptible to attack. In some cases. 
the products of the proteolytic digestion of these proteins by 
calpain are distinctive and persistent over time. Since 
25 cytoskeletal proteins are major components of certain types 
of cells. this provides a simple method of detecting calpain 
activity in cells and tissues. Thus, calpain activation can be 
measured indirectly by assaying the proteolysis of the 
cytoskeletal protein spectrin, which produces a large, dis-
30 tinctive and biologically persistent breakdown product when 
attacked by calpain [Siman, Baudry, and Lynch. Proc. Natl 
Acad. Sci. USA 81. 3572-3576 (1984); incorporated herein 
by reference]. Activation of calpains and/or accumulation of 
breakdown products of cytoskeletal elements has been 
35 observed in neural tissues of mammals exposed to a wide 
variety of neurodegenerative diseases and conditions. For 
example, these phenomena have been observed following 
ischemia in gerbils and rats, following stroke in humans. 
following administration of the toxins kainate, trimethyltin 
40 or colchicine in rats. and in human Alzheimer's disease. 
Several inhibitors of calpain have been described includ-
ing peptide aldehydes such as Ac-Leu-Leu-Nle-H and 
leupeptin (Ac-Leu-Leu-Arg-H). as well as epoxysuc-
cinates such as B-64. These compounds are not especially 
45 useful at inhibiting calpain in neural tissue in vivo because 
they are poorly membrane permeant and. accordingly. are 
not likely to cross the blood brain barrier very well. Also, 
many of these inhibitors have poor specificity and will 
inhibit a wide variety of proteases in addition to calpain. 
50 Other classes of compounds which inhibit cysteine proteases 
include peptide diazomethyl ketone (Rich. D. H., in Pro-
tease Inhibitors, Barrett A. J .. and Salversen. G .• Eds .. 
Elsevier. N.Y.. 1986, pp 153-178; incorporated herein by 
reference). Peptide diazomethyl ketones are potentially car-
Amino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260. 14-42 
(1985) for nomenclature rules; incorporated herein by 
reference]. An amino acid residue (AA) in a peptide or 
inhibitor structure refers to the part structure -NH-
CHR 1-CO-. where R1 is the side chain of the amino acid 
residue AA. A peptide a-ketoester residue would be desig-
nated -AA-CO-OR which represents the part structure 
-NH-CHR1-CO-CO-OR. Thus. the ethyl ketoester 
derived from benzoyl alanine would be designated 
Bz-Ala-CO-OEt which represents C6H5CO-NH-
CHMe-CO-CO-OEt. Peptide ketoamide residues 
would be designated -AA-CO-NH-R. Thus, the ethyl 
keto amide derived from Z-Leu-Phe--OH would be 
designated Z--Leu-Phe-CO-NH-Et which represents 65 
C6H5CH20CO-NH-CH(CH2CHMe2}-CO-NH-CH 
(CH2Ph)-CO-CO-NH-Et. 
55 cinogenic and are thought to be poorly membrane permeant 
and to have low specificity. Thus, no effective therapy has 
yet been developed for most neurodegenerative diseases and 
conditions. Millions of individuals suffer from neurodegen-
erative diseases and thus. there is a need for therapies 
60 effective in treating and preventing these diseases and con-
ditions. 
Cathepsin Bis involved in muscular dystrophy, myocar-
dial tissue damage. tumor metastasis, and bone resorption. 
In addition, a number of viral processing enzymes. which 
are essential for viral infection. are cysteine proteases. 
Inhibitors of cysteine proteases would have multiple thera-
peutic uses. 
5,763,576 
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Serine Proteases. Serine proteases play critical roles in Hanson and Harker, Proc. Natl. Acad. Sci. 85. 3184-3188 
several physiological processes such as digestion, blood (1988); 7-Amino-4-chloro-3-(3-isothiureidopropoxy) 
coagulation. complement activation. fibrinolysis. viral isocoumarin (ACTTIC). Oweida, Ku. Lumsden. Kam. and 
infection. fertilization. and reproduction. Serine proteases Powers. Thrombos. Res. 58. 191-197 (1990); incorporated 
are not only a physiological necessity. but also a potential 5 herein by reference). 
hazard if they are not controlled. Uncontrolled proteolysis Ketoesters. A few amino acid and peptide ketoesters and 
by elastases may cause pancreatitis. emphysema. rheuma- ketoacids have been previously reported. Cornforth and 
toid arthritis. bronchial inflammation and adult respiratory Cornforth [J. Chem. Soc., 93-96 (1953); incorporated herein 
distress syndrome. It has been suggested that a new trypsin- by reference] report the synthesis of the ketoacids 
like cellular enzyme (tryptase) is involved in the infection of 10 PhCH
2
CO-Gly-CO-OH and Ac-Gly-CO-OH 
human immunodeficiency virus type 1 [HIV-1; Hattori et al.. upon hydrolysis of heterocyclic molecules. Charles et al. [ J. 
FEBS Letters 248. pp. 48-52 ( 1989) ]. which is a causative Chem. Soc. Perkin/, 1139-1146 (1980); incorporated herein 
agent of acquired immunodeficiency syndrome (AIDS). by reference) use ketoesters for the synthesis of bicyclic 
Plasmin is involved in tumor invasiveness. tissue heterocycles. They report the synthesis of n-BuCO-Ala-
remodeling, blistering. and clot dissociation. Accordingly. 15 CO-OEt. PrCO-Ala-CO-OEt. cyclopentylCO-
specific and selective inhibitors of these proteases should be Ala-CO-OEt. PrCO-PhGly-CO-OEt. and 
potent anticoagulants. anti-inflammtory agents. anti-tumor Bz-Ala-CO- OEt. Hori et al. [Peptides: Structure and 
agents and anti-viral agents useful in the treatment of Function-Proceedings of the Ninth American Peptide Sym-
protease-related diseases [Powers and Harper. Proteinase posium (Deber. Hruby, and Kopple. Eds.) Pierce Chemical 
Inhibitors, pp 55-152. Barrett and Salvesen. eds .. Elsevier. 20 Co .• pp 819-822 (1985); incorporated herein by reference) 
(1986); incorporated herein by reference]. In vitro proteoly- report Bz-Ala-CO-OEt. Bz-Ala-CO-OH. 
sis by chymotrypsin. trypsin or the elastase family is a Z-Ala-Ala-Abu-CO-OEt. Z-Ala-Ala-Abu-
serious problem in the production. purification. isolation. CO-OBzl. and Z-Ala-Ala-Ala-Ala-CO-OEt 
transport or storage of peptides and proteins. (SEQ ID NO: 1) (Abu=2-aminobutanoic acid or 
Elastase inhibitors are anti-inflammatory agents which 25 a-aminobutyric acid) and report that these compounds 
can be used to treat elastase-associated inflammation includ- inhibit elastase. Trainer [Trends Phann. Sci. 8. 303-307 
ing rheumatoid arthritis and emphysema. Although the natu- (1987); incorporated herein by reference] comments on one 
rally occurring protease inhibitor. al-protease inhibitor (al- of this compounds. Burkhart. J .• Peet. N. P .. and Bey. P. 
PI) has been used to treat patients with emphysema. this [Tetrahedron Lett. 29. 3433-3436 (1988); incorporated 
protein inhibitor is not widely used clinically due to the high 30 herein by reference) report the synthesis of Z--Val-Phe-
dosage needed for treatment and the difficulty of producing CO-OMe and Bz-Phe-CO-OMe. 
large quantities. Therefore, small molecular weight elastase Mehdi et al.. [Biochem. Biophys. Res. Comm. 166. 
inhibitors are needed for therapy. Other low molecular 595-600 (1990); incorporated herein by reference[ report 
weight elastase inhibitors have utility for the treatment of the inhibition of human neutrophil elastase and cathepsin G 
emphysema and inflammation (see: 1-carpapenem-3- 35 by peptide a-ketoesters. Angelastro et al., [J. Med. Chem. 
carboxylic esters as anti-inflammatory agents, U.S. Pat No. 33. 13-16 (1990); incorporated herein by reference] report 
4.493.839; N-carboxyl-thienamycin esters and analogs some a-ketoesters which are inhibitors of calpain and chy-
thereof as anti-inflammatory agents. U.S. Pat No. 4,495. motrypsin. Hu and Abeles [An:h Biochem. Biophys. 281. 
197; incorporated herein by reference). 271-274 (1990)]; incorporated herein by reference] report 
Anticoagulants and antithrombotic drugs are used in a 40 some peptidyl a-ketoamides and a-ketoacids which are 
variety of thrombotic disorders. The 1990 Physician's Desk inhibitors of cathepsin B and papain. Peet et al. [ J. Med. 
Reference lists several anticoagulant drugs (heparin, prota- Chem. 33. 394-407 (1990); incorporated herein by 
mine sulfate and warfarin), a few antiplatelet drugs (aspirin) reference] report some peptidyl a-ketoesters which are 
and several thrombolytic agents. Heparin and warfarin are inhibitors of porcine pancreatic elastase, human neutrophil 
commonly used clinically for prevention and treatment ?f 45 elastase, and rat & human neutrophil cathepsin G. 
~e~o~s thrombosis and p_ulmon~ embolism. ~epann Ketoarnides. A single peptide ketoarnide is reported in the 
inhibits the blood coagulation a~v11?' _by ac~leratin~ the literature by Hu and Abeles [An:h Biochem. Biophys. 281, 
binding of natural plasma protease m~b1tor antithr~mb~ ill 271-27 4 ( 1990) ]. This compound z-phe-NHCH2CO-
with coagulation factors. and warfann acts as a. v1tarmn K CO-NH-Et or Z--Phe-Gly-CO-NH-Et is reported 
antagonist and inhibits the synthesis of ~aguatio? factors. so to be an inhibitor of papain (K.i=l.5 µM) and cathepsin B 
None of the anticoagulant drugs, antithro~botic dru~s. (Kr=4 µM). 
fibrinolytic agents and antiplatelet drugs are highly effective 
in all clinical situations and many induce side reactions [Von 
Kaulla. Burger's Medicinal Chemistry, Part II, pp 
1081-1132. Wolff. ed., (1979); incorporated herein by 55 
reference]. Coagulation disorders such as disseminated 
intravascular coagulation. bleeding complications of medi-
cal and surgical procedures and bleeding complications of 
systemic illness are still difficult to manage [Ingram. Bro-
zovic and Slater. Bleeding Disorders, pp 1-413. Blackwell 60 
Scientific Publications, (1982); incorporated herein by 
reference]. In the treatment of patients with coagulation 
problems. anticoagulant or antithrombotic agents of diverse 
mechanisms are urgently sought in order to provide better 
medical care. Inhibitors for the trypsin-like enzymes 65 
involved in blood coagulation are useful anticoagulants in 
vivo [see for example: H-D-Phe-Pro--Arg-CH2Cl. 
SUMMARY OF THE INVENITON 
We have discovered that peptide and amino acid 
a-ketoamide derivatives are a novel group of inhibitors for 
serine proteases and cysteine proteases. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of the 
enzyme. We have discovered that peptide a-ketoamide 
derivatives. which have an amino acid sequence similar to 
that of good substrates for a particular protease. are good 
inhibitors for that protease. Thus. we are able to predict the 
structures of new inhibitors for other serine and cysteine 
proteases based on knowledge of their substrate specificities. 
We have discovered some peptide u-ketoamide deriva-
tives which are specific inhibitors for chymotrypsin. Chy-
motrypsin and chymotrypsin-like enzymes hydrolyze pep-
5,763,576 
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tide bonds where P 1 amino acid is Trp. 'fyr. Phe. Met, Leu 
or other amino acid residues which contain aromatic or large 
alkyl side chains. Inhibitors with these residues at P 1 are 
good chymotrypsin and chymase inhibitors. Trypsin and 
trypsin-like enzymes normally cleave peptide bonds in pro- 5 
teins and peptides where the amino acid residue on the 
carbonyl side of the split bond (P 1 residue) is Lys or Arg. We 
show that peptide a-ketoamide derivatives which have Lys 
or Arg at P 1 will be good inhibitors for these enzymes. 
Elastase and elastase-like enzymes cleave peptide bonds 10 
where the P 1 amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. We shown that inhibitors with these 
residues at P1 are good elastase inhibitors. All of the above 
enzymes have extensive secondary specificity and recognize 
amino acid residues removed from the P 1 residue. 15 
The peptide a-ketoamide derivatives are also novel and 
potent inhibitors of cysteine proteases including calpains 
and cathepsin B. The calpain inhibitors are useful for 
treatment of various neurodegenerative diseases and 
conditions, including ischemia. stroke, and Alzheimer's 20 
disease. 
The new protease inhibitors, especially the elastase 
inhibitors. trypsin inhibitors. and chymase inhibitors are 
useful for controlling tissue damage and various inflamma-
tory conditions mediated by proteases such as blistering. The 25 
inhibitors for blood coagulation enzymes will be useful 
anticoagulants and could be used to treat thrombosis. 
The peptide and amino acid a-ketoamide derivatives are 
also useful in vitro for inhibiting trypsin, eJastase. chymot-
rypsin and other serine proteases of similar specificity, and 30 
for inhibiting serine proteases in general. The inhibitors can 
be used to identify new proteolytic enzymes encountered in 
research. They can also be used in research and industrially 
to prevent undesired proteolysis that occurs during the 
production, isolation, purification. transport and storage of 
35 
valuable peptides and proteins. Such proteolysis often 
destroys or alters the activity and/or function of the peptides 
and proteins. Uses would include the addition of the inhibi-
tors to antibodies, enzymes, plasma proteins. tissue extracts 
or other proteins and peptides which are widely sold for use 
in clinical analyses, biomedical research. and for many other 40 
reasons. For some uses a specific inhibitor would be 
desirable, while in other cases, an inhibitor with general 
specificity would be preferred. 
6 
tors may be useful as therapeutic agents for treatment of 
neurodegeneration. viral infections, muscular dystrophy. 
myocardial tissue damage. tumor metastasis. and bone 
resorption. 
The novel class of dipeptide a-ketoamides have the 
following structural formula: 
M 1-AA-NH-CHR2-CO-CO--NR3R4 
or a pharmaceutically acceptable salt. wherein 
M 1 represents H. NH 2-CO-. NH 2--CS-. NH2-
S02-. X-NH-CO--. X2N-CO-. X-NH-CS-. 
X2N-CS-. X-NH-S02-. X2N-S02-, X--CO-. 
X-CS-. X-S02-, X-0-CO--. or X-0-CS-; 
xis selected from the group consisting of cl-10 alkyl. 
C1_10 fiuoroalkyl. C1_10 alkyl substituted with J, C1_10 fiuo-
roalkyl substituted with J, 1-admantyl. 9-fiuorenyl. phenyl. 
phenyl substituted with K, phenyl disubstituted with K. 
phenyl trisubstituted with K. naphthyl. naphthyl substituted 
with K. naphthyl disubstituted with K. naphthyl trisubsti-
tuted with K. cl-10 alkyl with an attached phenyl group. 
C1_10 alkyl with two attached phenyl groups. C1_10 alkyl 
with an attached phenyl group substituted with K. C1_10 
alkyl with two attached phenyl groups substituted with K, 
C1_10 alkyl with an attached phenoxy group. and C1_10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH. CN. N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C1_10 alkyl-0--CO--. C1_10 alkyl-0--CO-
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl. C1_10 alkoxy, N02• CN. OH, 
C02H. amino, C1_10 alkylamino, C2_12 dialkylamino. C1_10 
acyl, and C1_10 alkoxy-CO-. and C1_10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine. 
valine. leucine, isoleucine. proline, methionine, methionine 
sulfoxide. phenylalanine, tryptophan. glycine, serine, 
threonine. cysteine. tyrosine. asparagine. glutarnine. aspartic 
acid. glutamic acid, lysine. arginine, histidine. 
phenylglycine. beta-alanine. norleucine, norvaline. alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid. 2-azetid.inecarboxylic acid, pipe-DETAJLED DESCRIPTION OF THE 
INVENTION 
Peptide a-ketoamides are transition state analog inhibi-
tors for serine proteases and cysteine proteases. Peptide 
a-ketoamides containing hydrophobic amino acid residues 
in the P 1 site have been found to be excellent inhibitors of 
serine proteases including porcine pancreatic elastase and 
bovine chymotrypsin. We show that peptide a-ketoamides 
containing amino acid residues with cationic side chains in 
the P 1 site will be excellent inhibitors of several serine 
proteases including bovine trypsin, bovine thrombin, human 
plasma kallikrein, porcine pancreatic kallikrein, human fac-
tor Xia and human plasmin. Peptide a-ketoamides contain-
ing amino acid residues with hydrophobic side chain at the 
P 1 site have also been found to be excellent inhibitors of 
several cysteine proteases including papain. cathepsin B. 
calpain L and calpain IT. These structures may be used in 
vivo to treat diseases such as emphysema, adult respiratory 
distress syndrome. .rheumatoid arthritis and pancreatitis 
which result from uncontrolled proteolysis by elastase. 
chymotrypsin, trypsin and related serine proteases. These 
inhibitors may be used in vitro to prevent proteolysis which 
occurs in the process of production. isolation, purification. 
storage or transport of peptides and proteins. These inhibi-
45 colinic acid (2-piperidine carboxylic acid). 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEti)--COOH. alpha-
aminoheptanoic acid. NH2--CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH. NH2-CH(CH 2-
so cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH. NH2-CH(CH2-cyclobutyl)--COOH. NH2--CH (CH2-cyclopropyl)-COOH. trifiuoroleucine, and 
hexafiuoroleucine; 
R2 is selected from the group consisting of C 1-s branched 
55 and unbranched alkyl. C1_8 branched and unbranched 
cyclized alkyl. and C1_8 branched and unbranched fiuoro-
alkyl; 
R3 and ~ are selected independently from the group 
consisting of H, C1 _20 alkyl. C3 _20 cyclized alkyl. C1_20 alkyl 
with a phenyl group attached to the cl-20 alkyl. c3-20 60 cyclized alkyl with an attached phenyl group. c3-20 alkyl 
with an attached phenyl group substituted with K, cl-20 
alkyl with an attached phenyl group disubstituted with K. 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K. c3-20 cyclized alkyl with an attached phenyl group 
65 substituted with K. C 1_10 alkyl with a morpholine [-N (CH2CH2)0] ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a piperidine ring attached through nitrogen 
5,763,576 
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to the alkyl. C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. --CH2CH20CH2CHpH, C1_10 with 
an attached 4-pyridyl group. C1_10 with an attached 
3-pyridyl group. C1_10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group. -NH--CH2CH2-(4-hydroxyphenyl), and -NH--CH2CH2-(3-indolyl). 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H. NH2--CO-. NH2--CS-. NH2-
S02-. X-NH--CO-. X2N--CO-. X-NH--CS-. 
X2N--CS-. X-NH-S02-. XiN-S02-· X--CO--. 
X--CS-. X-S02-. X---0-CO--. or X---0-CS-; 
X is selected from the group consisting of C1_10 alkyl. 
C1_10 fiuoroalkyL C1_10 alkyl substituted with J. C1_10 fiuo-
roalkyl substituted with J, 1-admantyl. 9-fiuorenyl, phenyl. 
phenyl substituted with K. phenyl disubstituted with K. 
phenyl trisubstituted with K. naphthyl, naphthyl substituted 
with K. naphthyl disubstituted with K. naphthyl trisubsti-
tuted with K. C1_10 alkyl with an attached phenyl group. 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K. 
C1_10 alkyl with an attached phenoxy group, and C1_10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
8 
0-ethylserine, S-methylcysteine, S-ethylcysteine. 
S-benzylcysteine. NH2--CH(CH2CHEti)--COOH. alpha-
aminoheptanoic acid, NH2--CH(CH2-1-napthyl)--COOH. 
NH2-CH(CH2-2-napthyl)-COOH. NH2-CH(CH2-
5 cyclohexyl)-COOH. NH2-CH(CH2-cyclopentyl)-
COOH. NH2--CH(CH2-cyclobutyl)--COOH. NH2--CH (CH2-cyclopropyl)-COOH. trifiuoroleucine. and 
hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
10 consisting of H. C1_20 alkyl. C3 _20 cyclized alkyl. C1_20 alkyl 
with a phenyl group attached to the C1_20 alkyl. C1_20 
cyclized alkyl with an attached phenyl group. cl-20 alkyl 
with an attached phenyl group substituted with K. C1_20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
15 K, c3-20 cyclized alkyl with an attached phenyl group 
substituted with K. C1_10 alkyl with a morpholine 1-N (CH2CH2)0] ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl. cl-10 alkyl with a pyrrolidine ring attached 
20 through nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl, --CH2CH20CH2CH20H. C1_10 with 
an attached 4-pyridyl group. C1_10 with an attached 
3-pyridyl group. cl-10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group. -NH--CH2CH2-
25 (4-hydroxyphenyl). and -NH--CH2CH2-(3-indolyl). 
The novel class of tripeptide a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
J is selected from the group consisting of halogen, COOH. 30 
OH. CN. N02• NH2• C1_10 al.koxy. C1_10 alkylamine, C2_12 
dialkylamine. cl-10 alkyl-0--CO-. cl-10 alkyl-0--CO--
NH-. and C1_10 alkyl-S-; 
M1 represents H. NH2--CO--, NH2--CS-. NH2-
S02-. X-NH--CO-. X2N--CO-, X-NH--CS-. 
X2N--CS-. X-NH-S02-. X2N-S02-. X--CO--. 
35 X--CS-. X-S02-. X---0-CO-. or X---0-CS-; 
K is selected from the group consisting of halogen, C1_10 
alkyl. C1-1o perfiuoroalkyl. C1_10 al.koxy. N02• CN. OH, 
C02H. amino. C1_10 alkylamino, C2_12 dialkylamino, 
C1--C10 acyl. and C1_10 al.koxy-CO--, and C1_10 alkyl-S-; 
AA 1 is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine. isoleucine. proline. methionine, methionine 
sulfoxide, phenylalanine, tryptophan, serine, threonine, 
cysteine. tyrosine. asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine. norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine. homoarginine. sarcosine. indoline 2-carboxylic 
acid. 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid). 0-methylserine. 
0-ethylserine, S-methylcysteine, S-ethylcysteine. 
S-benzylcysteine, NH2--CH( CH2CHEt2)--COOH. alpha-
aminoheptanoic acid, NH2--CH(CH2-1-napthyl)--COOH. 
NH 2--CH(CH2-2-napthyl)-COOH. NH2-CH(CH 2-
cyclohexyl)-COOH. NH2-CH(CH2-cyclopentyl)-
COOH. NH2--CH(CH2-cyclobutyl)--COOH, NH2--CH (CH 2-cyclopropyl)-COOH. trifiuoroleucine, and 
hexafiuoroleucine; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine. isoleucine, proline. methionine, methionine 
sulfoxide, phenylalanine, tryptophan. glycine, serine. 
threonine, cysteine. tyrosine, asparagine, glutamine. aspartic 
acid, glutamic acid, lysine. arginine, histidine. 
phenylglycine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline. ornithine, homoarginine. sarcosine. indo-
line 2-carboxylic acid. 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid). 0-methylserine, 
x is selected from the group consisting of cl-10 alkyl 
C1_10 fiuoroalkyl. C1_10 alkyl substituted with J. C1_10 ftuo-
roalkyl substituted with J, 1-admantyl. 9-fiuorenyl. phenyl. 
phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K. naphthyl. naphthyl substituted 
40 with K, naphthyl disubstituted with K. naphthyl trisubsti-
tuted with K, cl-10 alkyl with an attached phenyl group, 
C1_10 alkyl with two attached phenyl groups, C1_10 alkyl 
with an attached phenyl group substituted with K, cl-10 
alkyl with two attached phenyl groups substituted with K. 
45 C1_10 alkyl with an attached phenoxy group. and C1_10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH. 
OH. CN, N02, NH2• C1_10 alkoxy. C1_10 alkylamine. C2_12 
so dialkylamine, C1_10 alkyl-0-CO-. C1_10 alkyl-0--CO--
NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C1_10 
alkyl. C1_10 perfiuoroalkyl, C1_10 al.koxy, N02, CN, OH. 
C02H. amino, C1_10 alkylamino, C2_12 dialkylamino, C1_10 
55 acyl, and c~-10 al.koxr-c0-. and cl-10 alkyl-S-; 
AA 1, AA , and AA are the same or different and are side 
chain blocked or unblocked amino acid with the L 
configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, proline, methionine, methionine 60 sulfoxide, phenylalanine, tryptophan. glycine. serine, 
threonine. cysteine. tyrosine, asparagine. glutamine, aspartic 
acid, glutamic acid. lysine. arginine, histidine. 
phenylglycine. beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, citrulline. 
65 hydroxyproline, ornithine, homoarginine, sarcosine, indo-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid). 0-rnethylserine, 
5,763,576 
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0-ethylserine. S-methylcysteine. S-ethylcysteine. 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH. alpha-
aminoheptanoic acid. NH2-CH(CHrl-napthyl)-COOH. 
NH2-CH(CH2-2-napthyl)-COOH. NH2-CH(CH 2 -
cyclohexyl)-COOH. NH 2-CH(CHrcyclopentyl)- 5 
COOH. NH2-CH(CH2-cyclobutyl)-COOH. NH2-CH 
(CHrcyclopropyl)-COOH. trifiuoroleucine, and 
hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C 1_20 alkyl. C3_20 cyclized alkyl. C 1_20 alkyl 10 
with a phenyl group attached to the C1_20 alkyl. C3_20 
cyclized alkyl with an attached phenyl group. c3-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K. 
C 1_20 alkyl with an attached phenyl group trisubstituted with 
K. c3-20 cyclized alkyl with an attached phenyl group 15 
substituted with K. C1_10 alkyl with a morpholine [-N 
(CH2CH~O] ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl. cl-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH group 20 
attached to the alkyl. -CH2CHpCH2CHpH. C1_10 with 
an attached 4-pyridyl group. cl-10 with an attached 
3-pyridyl group. cl-10 with an attached 2-pyridyl group. 
C1_10 with an attached cyclohexyl group. -NH-CH2CH2-(4-hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 25 
The novel class of tetrapeptide a-ketoamides have the 
following structural formula: 
30 
10 
0-ethylserine, S-methylcysteine. S-ethylcysteine, 
S-benzylcysteine, NH2-CH(CH2CffEti)-COOH. alpha-
aminoheptanoic acid. NH2-CH(CH2-l-napthyl)-COOH. 
NH2-CH(CH2-2-napthyl)-COOH. NH 2-CH(CH2-
cyclohexyl)-COOH. NH2-CH(CH2-cyclopentyl)-
COOH. NH2-CH(CH2-cyclobutyl)-COOH. NH2-CH (CH2-cyclopropyl)-COOH, trifiuoroleucine. and 
hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C 1_20 alkyl. C3_20 cyclized alkyl. C1_20 alkyl 
with a phenyl group attached to the C1_20 alkyl. C3_20 
cyclized alkyl with an attached phenyl group. c3-20 alkyl 
with an attached phenyl group substituted with K. C1_20 
alkyl with an attached phenyl group disubstituted with K. 
C1_20 alkyl with an attached phenyl group trisubstituted with 
K. cl-20 cyclized alkyl with an attached phenyl group 
substituted with K. C1_10 alkyl with a morpholine 1-N (CH2CH2)0] ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl. C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. -CH2CH20CH2CH20H. C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group. 
C1_10 with an attached cyclohexyl group. -NH-CH2CH2-( 4-hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 
The novel class of amino acid a-ketoamides have the 
following structural formula: 
M1-AA-CO-NR3R.. 
or a phannaceutically acceptable salt, wherein M1 represents or a pharmaceutically acceptable salt. wherein 
H. NH2-CO-. NH2-CS-. NH2-S02-· X-NH- M1 represents H. NH2-CO-. NH2-CS-. NH2-
CO-. X2N-CO-. X-NH-CS-. X2N-CS-. S02-, X-NH-CO-. X2N-CO-. X-NH-CS-, 
X-NH-S02-. X2N-S02-, X-CO-. X-CS-. X2N-CS-, X-NH-S02-. X2N-S02-. X-CO-. 
X-802-. X--0-CO-. or X-0-CS-; 35 X-CS-. X-S02-. X-0-CO-. or X-0--CS-; 
X is selected from the group consisting of C1_10 alkyl, Xis selected from the group consisting of C1_10 alkyl. 
C1_10 :fiuoroalkyl, C1_10 alkyl substituted with J, C1_10 fluo- C1_10 fluoroalkyl. C1_10 alkyl substituted with J. C1_10 fluo-
roalkyl substituted with-J, 1-admantyl. 9-:fiuorenyl. phenyl. roalkyl substituted with J. 1-admantyl. 9-fluorenyl. phenyl. 
phenyl substituted with K. phenyl disubstituted with K. phenyl substituted with K. phenyl disubstituted with K. 
phenyl trisubstituted with K. naphthyl. naphthyl substituted phenyl trisubstituted with K. naphthyl. naphthyl substituted 
with K. naphthyl disubstituted with K. naphthyl trisubsti- 40 with K. naphthyl disubstituted with K. naphthyl trisubsti-
tuted with K. C1_10 alkyl with an attached phenyl group. tuted with K, C1_10 alkyl with an attached phenyl group. 
C1_10 alkyl with two attached phenyl groups. C1_10 alkyl C1_10 alkyl with two attached phenyl groups. C1_10 alkyl 
with an attached phenyl group substituted with K. C1_10 with an attached phenyl group substituted with K. C1_10 
alkyl with two attached phenyl groups substituted with K. alkyl with two attached phenyl groups substituted with K. 
C1_10 alkyl with an attached phenoxy group. and C1_10 alkyl 45 C1_10 alkyl with an attached phenoxy group. and C1_10 alkyl 
with an attached phenoxy group substituted with K on the with an attached phenoxy group substituted with K on the 
phenoxy group; phenoxy group; 
J is selected from the group consisting of halogen, COOH. J is selected from the group consisting of halogen. COOH. 
OH. CN, N02• NH2• C1_10 alkoxy. C1_10 alkylamine, C2_12 OH, CN. N02• NH2• C1_10 alkoxy. C1_10 alkylamine. C2_12 
dialk:ylamine. C1_10 alkyl-0-CO-. C1_10 alkyl-0-CO- 50 dialkylamine. C1_10 alkyl-0-CO-. C1_10 alkyl-0-CO-
NH-, and C1_10 alk:yl-S-; NH-, and C1_10 alk:yl-S-; 
K is selected from the group consisting of halogen. C1_10 K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalk:yl. C1_10 alkoxy, N02• CN. OH. alkyl. C1_10 perfluoroalkyl. C1_10 alkoxy. N02• CN. OH. 
C02H. amino. C1_10 alkylamino, C2_12 dialkylamino, C02H, amino, C1_10 alkylamino. C2_12 dialkylamino. C1_10 
C1-C10 ac~l. and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 55 acyl. and C1_10 alkoxy-CO-. and C1_10 alkyl-S-; AA 1, AA • AA3 and AA 4 are the same or different and are AA is a side chain blocked or unblocked amino acid with 
side chain blocked or unblocked amino acid with the L the L configuration. D configuration, or no chirality at the 
configuration. D configuration, or no chirality at the a-carbon selected from the group consisting of alanine. 
a-carbon selected from the group consisting of alanine. valine, leucine, isoleucine. proline. methionine. methionine 
valine. leucine. isoleucine, proline, methionine, methionine sulfoxide, phenylalanine. tryptophan. glycine. serine. 
sulfoxide. phenylalanine. tryptophan, glycine, serine, 60 threonine. cysteine. tyrosine. asparagine, glutamine, aspartic 
threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid. lysine, arginine, histidine. 
acid. glutamic acid, lysine. arginine. histidine, phenylglycine, beta-alanine. norleucine. norvaline. alpha-
phenylglycine. beta-alanine. norleucine. norvaline, alpha- aminobutyric acid, epsilon-aminocaproic acid, citrulline. 
aminobutyric acid. epsilon-aminocaproic acid. citrulline, hydroxyproline. ornithine. homoarginine, sarcosine. indo-
hydroxyproline, ornithine, homoarginine, sarcosine, indo- 65 line 2-carboxylic acid. 2-azetidinecarboxylic acid. pipe-
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe- colinic acid (2-piperidine carboxylic acid), 0-methylserine. 
colinic acid (2-piperidine carboxylic acid), 0-methylserine. 0-ethylserine. S-methylcysteine. S-ethylcysteine. 
5.763,576 
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S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH. alpha-
aminoheptanoic acid. NH2-CH(CH2-l-napthyl)-COOH. 
NH 2-CH(CH2-2-napthyl)-COOH. NH 2-CH(CH 2-
cyclohexyl)-COOH. NH2-CH(CH2-cyclopentyl)-
COOH. NH2-CH(CH2-cyclobutyl)-COOH. NH2-CH (CH 2-cyclopropyl)-COOH. trifluoroleucine, and 
hexafluoroleucine; 
R3 and R4 are selected independently from the group 
consisting ofH. C1_20 alkyl. C1_20 cyclized alkyl. C1 _20 alkyl 
with a phenyl group attached to the C1_20 alkyl. C3 _20 
cyclized alkyl with an attached phenyl group. c3-20 alkyl 
with an attached phenyl group substituted with K. cl-20 
alkyl with an attached phenyl group disubstituted with K. 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K. C3 _20 cyclized alkyl with an attached phenyl group 
substituted with K. C1_10 alkyl with a morpholine [-N (CH2CH00J ring attached through nitrogen to the alkyl. 
cl-10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl. C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. -CH2CH20CH2CH20H. C1 _10 with 
an attached 4-pyridyl group. C1_10 with an attached 
3-pyridyl group. C1_10 with an attached 2-pyridyl group. 
C1_10 with an attached cyclohexyl group, -NH-CH2CH2-( 4-hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 
The following compounds are representatives of the 
invention: 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH-{CH0~ 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-{CH2)iPh 
Z-Leu-Abu-CONH-{CH2h-N(CH2CH2)i0 
Z-Leu-Abu-CONH-{CH2).,CH3 
Z-Leu-Abu-CONH-{CH2}i0H 
Z-Leu-Abu-CONH-{CH2)20(CH2)zOH 
Z-Leu-Abu-CONH-{CH2)17CH3 
Z-Leu-Abu-CONH-CH2-C6H3(0CH3)2 
Z-Leu-Abu-CONH-CH2-C4H4N 
Materials and Methods. HEPES, heparin, and A23187 
were obtained from Calbiochem. Suc-Leu-'fyr-AMC 
and chromogenic substrates were obtained from Sigma. 
Calpain I was purified from human erythrocytes according 
to the method of Kitahara (Kitahara et al., J. Biochem 95. 
1759-1766) omitting the Blue-Sepharose step. Calpain II 
from rabbit muscle and cathepsin B were purchased from 
Sigma. Papain was purchased from Calbiochem.. 
Assay of Inhibitory Potency. Peptide a-ketoamides were 
assayed as reversible enzyme inhibitors. Various concentra-
tions of inhibitors in Me2SO were added to the assay mixture 
which contained buffer and substrate. The reaction was 
started by the addition of the enzyme and the hydrolysis 
rates were followed spectrophotometrically or fiuorimetri-
cally. 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-'fyr-AMC [Sasaki 
et al.,J. Biol. Chem 259.12489-12494 (1984); incoiporated 
herein by reference], and the AMC (7-amino-4-
methylcoumarin) release was followed fiuorimetrically 
(excitation at 380 run. and emmision at 460 nm). Calpains 
were assayed in 25 mM Tris pH=8.0. 10 mM CaCl2. 
Fluorescence was followed using a Gilson FL-lA fluorom-
eter or a Perkin-Ebner 203 Fluorescence spectrometer. 
12 
Cathepsin B was assayed in 20 mM sodium acetate pH=5.2. 
0.5 mM dithiothreitol using Bz-Phe-Val-Arg-p-
nitroanilide as substrate. Alternately. cathepsin B was 
assayed with Z-Arg-Arg-AFC [Barrett and Kirschke, 
5 Methods EnzyWJl. 80. 535-561 (1981); incorporated herein by reference). and the AFC (7-amino-4-
trifluoromethylcoumarin) release was followed fluorimetri-
cally (excitation at 400 nm and emrnision at 505 nm). Papain 
was assayed in 100 mM KP04 , 1 mM EDTA. 2.5 mM 
cysteine pH=6.0 using Bz-Arg-AMC or Bz-Arg-NA 
10 [Kanaoka et al .• Chem Phann. Bull 25. 3126-3128 (1977); 
incoipOrated herein by reference] as a substrate. The AMC 
(7-arnino-4-methylcoumarin) release was followed fluori-
metrically (excitation at 380 nm. and emmision at 460 nm). 
Enzymatic hydrolysis rates were measured at various sub-
15 strate and inhibitor concentrations, and K 1 values were 
determined by either Lineweaver-Burk plots or Dixon plots. 
AO. lM Hepes. 0.5M NaCl. pH 7 .5 buffer was utilized for 
human leukocyte elastase (HLE), porcine pancreatic elastase 
(PPE). chymotrypsin and cathepsin G. A 0.1 Hepes, O.OlM 
20 
CaC12, pH 7.5 buffer was utilized for trypsin, plasmin. and 
coagulation enzymes. A 50 mM Tris.HCl. 2 mM EDTA. 5 
mM cysteine, pH 7 .5 was used as a buffer for papain. A 88 
mM KH2P04 • 12 mM N~HP04• 1.33 mM EDTA. 2.7 mM 
cysteine. pH 6.0 solution was used as a buffer for cathepsin 
B. A 20 mM Hepes, 10 mM CaC12. 10 mM mercatoethanol, 
25 pH 7 .2 buffer was utilized for calpain I and calpain IL 
HLE and PPB were assayed with MeO-Suc-Ala-
Ala-Pro-Val-NA and Sue-Ala-Ala-Ala-NA. 
respectively [Nakajima et al., J. Biol. Chem. 254. 
4027-4032 (1979); incorporated herein by reference]. 
30 Human leukocyte cathepsin G and chymotrypsin Aa. were 
assayed with Suc-Val-Pro-Phe-NA [Tanaka et al., 
Biochemistry 24, 2040-2047 (1985); incorporated herein by 
reference). The hydrolysis of peptide 4-nitroanilides was 
measured at 410 nm [e410=8800 M-1cm-1; Erlanger et al., 
35 Arr:h Biochem. Biophys. 95. pp 271-278 (1961); incoipO-
rated herein by reference]. Trypsin. thrombin, human plasma 
kallikrein, porcine pancreatic kallikrein, human factor XIa. 
and human plasmin were assayed with Z-Arg-SBzl or 
Z-Gly-Arg-SBu-i [McRae et al .. Biochemistry 20, 
7196-7206 (1981); incorporated herein by reference]. All 
40 peptide thioester hydrolysis rates were measured with assay 
mixtures containing 4.4' -dithiodipyridine [ e324= 19800 
M-1cm-1; Grasetti & Murray, Arch Biochem Biophys. 119. 
41-49 (1967); incorporated herein by reference]. 
Platelet membrane permeability assay. Calpain-mediated 
45 breakdown of spectrin was measured by quantitative densi-
tometry of the calpain-specific 150/155 kDa spectrin frag-
ment doublet [see Simao et al., Proc. Natl. Acad. Sci. USA 
81. 3572-3576 (1984)]. Platelets were isolated by a modi-
fication of the method of Ferrell and Martin [J. Biol. Chem. 
50 264, 20723-20729 (1989)]. Blood (15-20 ml) was drawn 
from male Sprague-Dawley rats into I/10th volume of 100 
mM EDTA-citrate, and centrifuged 10 minutes at 2000 rpm 
in a clinical centrifuge at room temperature. The plasma was 
resuspended in 15 ml of buffer 1 (136 mM NaCl. 2.7 mM 
55 KCl. 0.42 mM NaH2ro4. 12 mM NaHC03. 2 mM MgCl2, 
2 mg/ml BSA (Sigma). 5.6 mM glucose. 22 mM Na3citrate 
pH 6.5) and platelets were isolated at 2200 rpm at room 
temperature for 10 minutes. Platelets were washed once in 
15 ml buffer L then resuspended to 107 cells/ml in buffer 2 
(136 mM NaCl, 2.7 mM KCl. 0.42 mM NaH;iP04• 12 mM 60 NaHC03 • 2mM MgCl, 1 mg/ml BSA (Sigma), 5.6 mM 
glucose. 20 mM HEPES (Sigma) pH 7.4) and allowed to 
"rest" for a minimum of 10 minutes at room temperature 
before use. 
Inhibitors were added from stock solutions made fresh in 
65 DMSO. 100 µl platelets, suspended to 107 cells/ml in buffer 
2, were incubated with 1 µl of an inhibitor solution for 5 
minutes at room temperature prior to the addition of 2 mM 
5,763576 
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Ca2+ and 1 uM A23187. After 10 minutes total exposure to 
inhibitor (5 minutes exposure to ionophore) at room 
temperature, platelets were reisolated at 14,000 rpm for 10 
sec in a Beckman microfuge, dissolved in SDS-PAGE 
sample buffer, and heated to 90° C. for 3 minutes. 5 Samples were subjected to SDS-PAGE in 4-12% gradient 
mini gels (Novex) and transferred to nitrocellulose 
(Schleicher and Schuell 0.45 um) by electroblotting. Filters 
were blocked for 10 minutes in 0.25% gelatin, 1 % BSA, 
0.25% triton XlOO. 0.9% NaCl, 10 mM Tris-Cl pH 7.5, 
incubated overnight in the same solution containing anti- IO 
body to rat spectrin, washed 3x10 minutes with 10 mM 
Tris-ClpH7.5, 0.5% triton X 100. incubated4hours in wash 
buffer plus alkaline phosphatase conjugated goat anti-rabbit 
antibody (Biorad). and washed as above. Blots were devel-
oped using the Biorad AP conjugate substrate kit. Quanti- 15 
tative densitometry was used to obtain values for the intact 
spectrin bands and the 150/155 kDa breakdown product 
doublet. 
Structure-Activity Relationships. Table I shows the inhi-
bition constants (K1) for cathepsin B. calpain I. and calpain 20 
II. Dipeptide a-ketoamides with Abu and Phe in the P 1 site 
and Leu in the P 2 site are potent inhibitors of calpain I and 
calpain II. Z-Leu-Abu-CONH-Et is a better inhibitor 
of calpain I than Z-Leu-Phe-CONH-Et by 14 fold 
Replacement of the Z group (PhCH20CO-) by similar 25 groups such as PhCH2CH2CO-. PhCH2CH2S02-. 
PhCH2NHCO-, and PhCH2NHCS- would also result in 
good inhibitor structures. The best inhibitor of calpain II is 
Z-Leu-Abu-CONH-{CH2)i-Ph. Changing the R3 
and R4 groups significantly improves the inhibitory potency 
toward calpain II. The best dipeptide inhibitors are those 30 
which have long alkyl side chains (e.g. Z-Leu-Abu-
CONH-{CH2:hCH3), alkyl side chains with phenyl substi-
tuted on the alkyl group (e.g. Z-Leu-Abu-CONH-
(CH2)2-Ph), or alkyl groups with a morpholine ring 
substituted on the alkyl group [e.g. Z-Leu-Abu- 35 
CONH-{CH2)3-Mpl. Mpl=-N(CH2CH2)20]. Dipeptide 
a-ketoamides with a small aliphatic amino acid residue or a 
Phe in the P 1 site are also good inhibitors for cathepsin B. 
The best inhibitor is Z-Leu-Abu-CONH-Et and 
replacement of the Z (PhCH20CO-) by PhCH2CH2CO-. 40 
PhCH2CH2S02-. PhCHiNIICO-. and PhCHiNIICS-
would also result in good inhibitor structures. 
TABLE I 
Inhibition of Cysteinc Proteases by Peptide cx-Ketoamides. 45 
Calpain Calpain Cath 
Peptide cx-Ketoamide I n B 
50 
Z-Leu-Abu-CONH-Et 0.5 0.23 2.4 
Z-LeU-.:.Abu-CONH-nPr 0.25 8 
Z-Leu-Abu-CONH-nBu 0.2 13 
Z-Leu-Abu-CONH-iBu 0.14 4 
Z-Leu-Abu-CONH-Bzl 0.35 2 
Z-Leu-Abu-CONH-CH2),-Ph 0.022 55 
Z-Leu-Abu-CONH-{CH,)3-Mpl 0.041 
Z-Leu-Abu-CONH-{CH,),CH3 0.019 
Z-Leu-Abu-CONH-{CH,)17CH, 
Z-Leu-Abu-CONH-{CH,),OH O.Q78 
Z-Leu-Abu-CONH-{CH,),O(CH2 ).,0H 0.16 
Z-Leu~he-CONH-Et 7.0 0.32 6 (j() 
Z-Leu-Phe-CONH-nPr 15.0 0.05 3 
Z-Leu~he-CONH-nBu O.D28 3 
Z-Leu~he-CONH-iBu 0.065 4 
Z-Leu~he-CONH-Bzl 0.046 
Z-Leu~he----CONH(CH,).,Ph 0.024 
65 
Table II shows the inhibition constants (K1) for PPelastase 
and chymotrypsin. Dipeptide a-ketoamides with Abu in the 
14 
P 1 site are potent inhibitors of PP elastase. The structures 
with medium sized straight-chain alkyl groups such as n-Pr 
and n-Bu were better inhibitors than a small alkyl (Et) or a 
branched alkyl (i-Bu). Dipeptide a-ketoamides with Phe in 
the P 1 site are moderate inhibitors of chymotrypsin. The 
inhibitor with R3=n-Bu and R4=H was the best in the series. 
In general the inhibitors were more potent at inhibiting 
cysteine protease than serine proteases. Extending the pep-
tide chain to tripeptide or tetrapeptide o:-ketoamides would 
improve the inhibitory potency toward serine proteases. 
TABLE II 
Inhibition of Serine Proteases by Peptide cx-Ketoamides. 
Peptide cx-Ketoamide 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-{CH,)2-Ph 
Z-Leu-Abu-CONH-{CH2),-Mpl 
Z-Leu-Abu-CONH-{CH2).,CH3 
Z-Leu-Abu-CONH-{CH2) 1,CH3 
Z-Leu-Abu-CONH-{CH,).,OH 
Z-Leu-Abu-CONH-{CH2).,0(CH2):,0H 
Z-Leu-Phe-CONH-Et 
Z-Leu~he-CONH-nPr 
Z-Leu~he-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu~he-CONH-Bzl 
Z-Leu~he-CONH(CH,),Ph 
K,(uMl 
pp 
Chymotrypsin elastase 
>150 
>300 
>300 
>300 
>300 
73 
18 
8 
24 
65 
2 
5 
40 
>150 
>300 
>100 
Peptide a-ketoamide were substantially more stable in 
both plasma and liver than the corresponding peptide 
o:-ketoesters (Table ill). The peptide o:-ketoamides were 
also much more effective in the platelet assay. Extending the 
R3 group to an alkyl group or an alkyl group substituted with 
a phenyl group increased the membrane permeability of the 
inhibitors as indicated by increased potency in the platelet 
assay. 
TABLE ill 
Half-lives in Plasma and in Liver and Activity in the Platelet Assay. 
Peptide a-Ketoamide or Ester 
Z-Leu-Abu-COOEt 
Z-Leu-Abu-COOn-Bu 
Z-Leu-Abu-COOBzl 
Z-Leu~u-Abu-COOEt 
2-NapS02-Leu--Leu-Abu-COOEt 
2-NapCO-Leu-Leu-Abu-COOEt 
Tos-Leu-I..eu-Abu-COOEt 
Z-Leu-Abu-COOH 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu~he-COOEt 
Z-Leu-Phe-COOnBu 
Z-Leu-Leu-Phe-COOBz 
Z-Leu~he-COOEt 
Z-Leu-Phe-COOH 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
1112 
platelet plasma 
42 
28 
++ 
40 
100 
30 
8 
1.5 
70 
2.0 
28 
1.5 
42 
+++ 
++ 
++ 
6.5 
1.7 
24 
38 
22 
2.8 
>60 
25 
30 
>60 
>60 
>60 
>60 
>60 
>60 
7.8 
7.7 
1.9 
1112 
liver 
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TABLE ID-continued 
Half-lives in Plasma and in Liver and Activity in the Platelet Assay. 
t112 t112 
Peptide a-Ketoamide or Ester platelet plasma liver 
Z-Leu-Phe-CONH(CH2 ),Ph 3.0 >60 
Z-Leu-Nle---COOEt 20 3.7 
Z-Leu-Nva---COOEt 40 2.8 
Z-Leu-Met---COOEt + 8 
+t+ = excellent activity; ++ = good activity, + = moderate activity; quanti-
tiative measurements not yet complete) 
Inhibition Mechanism. A crystal structure of one 
a-ketoester bound into the active site of porcine pancreatic 
elastase has been completed and a schematic drawing of the 
interactions observed is shown below. The active site Ser-
195 oxygen of the enzyme has added to the carbonyl group 
of the ketoester to form a tetrahedral intermediate which is 
stabilized by interactions with the oxyanion hole. This 
structure resembles the tetrahedral intermediate involved in 
peptide bond hydrolysis and proves that a-ketoesters are 
transition-state analogs. His-57 is hydrogen bonded to the 
carbonyl group of the ester functional group, the peptide 
backbone on a section of PPE's backbone hydrogen bonds 
to the inhibitor to form a [3-sheet, and the benzyl ester is 
directed toward the s· subsites. The side chain of the p 1 
amino acid residue is located in the S 1 pocket of the enzyme. 
Interactions with ketoamides would be similar except for 
that there would be the possibility of forming an additional 
hydrogen bond with the NH group of the ketoamide func-
tional group if R3 or R4 was H. If R3 and/or ~ are longer 
substutuents. then they would make favorable interactions 
with the S' subsites of the enzyme. 
The active site of cysteine proteases share several features 
16 
that are found in complexes of a particular individual 
enzyme with its substrates. In order to design an inhibitor for 
a particular serine or cysteine protease, it is necessary to: 1) 
find the amino acid sequences of good peptide substrates for 
5 that enzyme, and 2) place those or similar amino acid 
sequences into a a-ketoamide structure. Additional interac-
tions with the enzyme can be obtained by tailoring the R 
group of the inhibitor to imitate the amino acid residues 
which are preferred by an individual protease at the s.· and 
10 S2' subsites. For example. ketoesters with R3 and/or 
R4=branched alkyl groups would interact effectively with 
serine and cysteine proteases which prefer Leu. Ile. and Val 
residues at P1' and/or P2', while amides with R=alkyl sub-
stituted with phenyl would interact effectively with serine 
15 and cysteine proteases which prefer Phe. Tyr. Ttp residues at 
P1' and/or P2'. Likewise. the M1 group can be tailored to 
interact with the S subsites of the enzyme. This design 
strategy will also work when other classes of peptide inhibi-
tors are used in place of the peptide substrate to gain 
20 information on the appropriate sequence to place in the 
ketoester. ketoacid. or ketoamide inhibitor. Thus. we are able 
to predict the structure of new inhibitors for other serine and 
cysteioe proteases based on knowledge of their substrate 
specificities. Once a good inhibitor structure for a particular 
25 enzyme is found. it is then possible to change other char-
acteristics such as solubility or hydrophobicity by adding 
substituents to the M 1 or R3 and R4 groups. 
Elastase is an enzyme which hydrolyzes most effectively 
tetra- and tripeptides having P 1 residues with small alkyl 
30 side chains such as Ala and Val. MeO--Suc-Ala-Ala-
Ala-Val-NA (SEQ ID N0:2) and Z-Ala-Ala-Ala-
Ala-NA (SEQ ID NO:l) are good substrates (NA=4-
oitroanilide). Thus the corresponding o:-ketoamide 
S' subsites 
His-57 
50 
in common with serine proteases including an active site 
histidine residue. In place of the Ser-195. cysteine proteases 55 
have an active site cysteine residue which would add to the 
ketooic carbonyl group of the peptide keto acids. keto esters. 
Z-Ala-Ala-Ala-DL-Ala-CO-NR3R4 and Me0-
Suc-Ala-Ala-Pro--DL-Abu-CO-NR3R4 will be 
excellent elastase inhibitors. Suc-Phe-Leu--Phe-NA is 
an excellent substrate for chymotrypsin. cathepsin G. and 
mast cell chymases. Thus. the corresponding a-ketoamide 
will be an excellent inhibitor for these chymotrypsin-like 
enzymes. In the case of the cysteine protease calpain, a good 
inhibitor sequence is Ac-Leu-Leu-Nle-H. We have 
found that ketoesters related in structure such as Z-Leu-
Abu-CO-NR3R4 and Z-Leu-Phe-CO-NR3~ are 
potent inhibitors for calpain. 
or ketoamides to form an adduct very similar to the structure 
depicted above except with a cysteine residue replacing the 
serioe-195 residue. Additional interactions would occur 60 
between the extended substrate binding site of the cysteine 
protease and the inhibitor which would increase the binding 
affinity and specificity of the inhibitors. The following structures are predicted to be potent inhibi-
65 tors for the listed enzymes. The inhibitor sequences were 
obtained from peptide substrate and/or inhibitor sequences 
in the protease literature. 
Inhibitor Design and Selection. The peptide and amino 
acid o:-ketoamide derivatives, as shown in the above crystal 
structure. bind to the enzymes using many of the interactions 
5,763,576 
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Z-Gly-Leu-Phe-CO-NR3 R4 
Me0-Suc-Ala-Ala-Pro-Met-CO-NR3R4 (SEQ ID NO: 3) 
Boc-Ala-Ala-Asp-CO-NR3R4 
Suc--Pro-Leu---Phe-CO-NR3R4 ...s Boo-AJa--AIA-Phe--00-NRJR. 
Boc--Oly-Leu~O-NR3R4, Suc-Phe--Leu-Phe-CO-NR3R4 
Boc-Ala-Ala-Glu--CO-NR3R4 
Z-Gly--Oly-Pro-CO-NR3R4 
Ala-Pro---CO-NR3R4 
Suc-Ala-Ala-Pro-Val-CO-NR3R4 (SEQ ID NO: 4) 
Suc-Lys(Cbz}-Val-Pro-Val-CO-NR3R4 (SEQ ID NO: 5), 
adamantyl-S02-Lys(COCH2CH2C02H}-Ala-
18 
for cathcpsin G and RMCP II 
tbr cathepsin G 
for hwnan lymphocyte granzyme B 
for RMCP I (RMCP = rat mast cell protease) 
for hwnan and dog skin chymase 
for S. aull!us V-8 protease 
for hwnan prolyl endopeptidase 
forDPP IV 
for PPE 
for hwnan leukocyte 
Val-CO-NR,R4, adamantyl-CH,CH,OCO--Dlu(O-t-Bu)--Pro--Val-CO-NR3R4, and 
adamantyl-S02-Lys(CO-C~C02H}-Ala-Val-{:0-NR3R, 
(neuttophil) elastase 
Suc-Ala-Ala-Pro-Leu-CO-NR3R, (SEQ ID NO: 6) 
Glu-Pbe-Lys---CO-NR3R, and Dns-Ala-Phe-Lys---CO-NR3R4 
D-Val-Gly-Arg-CO-NR3R4 and Dns--Glu-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-(:0-NR3 R, and Z-Thp-Arg-CO-NR3R, 
Z-Lys--Arg-CO-NR3R4 
Z-Gly-Arg-CO-NR3R, 
Z-Ile-Ala-Gly-Arg-CO-NR3R4 (SEQ ID NO: 7) 
Glu-Gly-Arg-CO-NR3R4 
Dns-Phe-Pro-Arg-CO-NR3R4 
Dns-Ile-Pro-Arg-CO-NR3R, 
Z-Thp-Arg-CO-NR,R4 
Z-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-CO-NR3R, 
Dns--Glu-Gly-Arg-CO-NR3R4 
D-Phe-Pro-Arg-CO-NR3 R,, D-MePhe-Pro-Arg-CO-NR3R4 , and 
Boc-D-Phe-Pro-Arg-CO-NR3R4 
Z-Phe-Gly-Arg-CO-NR3R4 
c1-e~.cH,OCO---Phe-Gly-CO-NR3R4 
C~5CH2NHCO--Oly-Phe-G!y-(:0-NR3R, 
R3 and ~ are selected independently from the group 
consisting ofH, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 alkyl 35 
with a phenyl group attached to the c3-20 alkyl, cl-20 
cyclized alkyl with an attached phenyl group, c3-20 alkyl 
with an attached phenyl group substituted with K. C 1_20 
alkyl with an attached phenyl group disubstituted with K. 
cl-20 alkyl with an attached phenyl group trisubstituted with 40 
K, C3 _20 cyclized alkyl with an attached phenyl group 
substituted with K. C1_10 alkyl with a morpholine [-N 
(CH2CH2)0] ring attached through nitrogen to the alkyl, 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl, C1_10 alkyl with a pyrrolidine ring attached 45 
through nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C 1 _10 with an attached 
3-pyridyl group, cl-10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group, -NH-CH2CH2- 50 
( 4-hydroxyphenyl), and -NH-CH2CH2-(3-indolyl). 
In Vitro Uses. To use the above inhibitors in vitro, they are 
dissolved in an organic solvent such as dimethylsulfoxide or 
ethanol, and are added to an aqueous solution containing 
serine and/or cysteine proteases. The final concentration of 55 
the organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine and 
cysteine protease inhibitors of this invention would be useful 
in a variety of experimental procedures where proteolysis is 
a significant problem. Inclusion of these inhibitors in a 60 
radioimmunoassay experiments would result in higher sen-
sitivity. The use of these inhibitors in plasma fractionation 
procedures would result in higher yields of valuable plasma 
proteins and would make purification of the proteins easier. 
The inhibitors disclosed here could be used in cloning 65 
experiments utilizing bacterial cultures. yeast and human 
cells to yield a purified cloned product in higher yield. 
for elastolytic proteinase from "Schistosoma 
mansoni'' 
for plasmin 
for factor Xa 
for porcine pancreatic and hwnan plasma 
kallikreins 
fur hmnan skin tryptase 
for hmnan lung tryptase 
tbr factors IXa, Xa, Xia, XIla and 
bovine plasma kallikrein 
for urokinase 
for plasmioogen activator 
for activated protein C 
for bovine factor IXa 
tbr bovine factor Xa and Xia 
for bovine factor Xlla 
for hwnan factor Xa 
for hwnan thrombin 
for trypsin 
for papain 
for cathepsin B 
The novel compounds of this invention are effective in the 
prevention of unnecessary proteolysis caused by 
chymotrypsin-lik:e and elastase-like enzymes in the process 
of purification, transport and storage of peptides and pro-
teins as shown in Table II by effective inhibition of chy-
motrypsin and elastase and other cysteine proteases. 
In Vivo Uses. Effective inhibitors of the proteolytic func-
tion of human leukocyte elastase and chymotrypsin-lik:e 
enzymes (fable m would have anti-inflammatory activity 
and can be used to treat and control emphysema, adult 
respiratory distress syndrome and rheumatoid arthritis. 
Effective inhibitors of the proteolytic function of chymot-
rypsin and pancreatic elastase (fable II) are effective for 
theraputic use in the treatment of pancreatitis. 
Peptide cx-ketoamide can be used to control protein 
turnover, muscular dystrophy, myocardial tissue damage. 
tumor metastasis, and bone resorption as shown in Table I by 
effective inhibition of lysosomal cathepsin B in buffer. 
Peptide cx-ketoamides can also be used as neuroprotectants 
or for the treatment of ischemia, stroke or Alzheimer's 
disease as shown in Table I by effective inhibiton of calpain 
I and calpain II. 
Considerable evidence has shown that leukocyte elastase 
and/or related enzymes play a role in tumor cell metastasis 
[Salo et al., Int. J. Cancer 30. pp 669-673 (1973); Kao et al .. 
Biochem. Biophys. Res. Comm. 105. pp 383-389 (1982); 
Powers, J. C. in Modification of Proteins, R. E. Feeney and 
J. R. Whitaker, eds., Adv. Chem. Ser 198.Amer. Chem. Soc .. 
Wash., D. C. pp 347-367 (1982); all incorporated herein by 
reference], therefore it is suggested that compounds of this 
invention may have anti-tumor activity. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction of 
lung elastin and alveoli. The destructive changes of lung 
5,763,576 
19 
parentchyma associated with pulmonary emphysema are 
caused by uncontrolled proteolysis in lung tissues [Janoff. 
Chest 83, 54-58 (1983); incorporated herein by reference]. 
20 
suspention. A composition in the form of an aqueous solu-
tion is obtained by dissolving the compounds of this inven-
tion in aqueous buffer solution of pH 4 to 6.5 and if desired. 
adding a polymeric binder. An oily formulation for topical A number of proteases have been shown to induce emphy-
sema in animals [Marco et al .. Am. Rev. Respir. Dis. 104. 
595-598 (1971); Kaplan. J. Lab. Clin. Med. 82. 349-356 5 application is obtained by suspending the compounds of this invention in an oil. optionally with the addition of a swelling 
agent such as aluminium stearate and/or a surfactant. ( 1973); incorporated herein by reference I. particularly human leukocyte elastase [Janoff. ibid 115. 461-478 (1977); 
incorporated herein by reference]. Leukocyte elastase and 
other mediators of inflammation also appear to play a role in 
10 diseases such as mucocutaneous lymph node syndrome 
[Reiger et al .. Eur. J. Pediatr. 140. 92-97 (1983); incorpo-
rated herein by reference! and adult respiratory distress 
syndrome [Stockley. Clinical Science 64. 119-126 (1983); 
Lee et al., N. Eng. J. Med. 304. 192-196 (1981); Rinaldo. 
ibid 301. 900-909 ( 1982); incorporated herein by reference]. 15 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of emphy-
sema and inflammation I Otterness et al .. editors. Advances 
in Inflammation Research. Vol. 11. Raven Press 1986; 
incorporated herein by reference). Prophylactic administra- 20 
tion of an inhibitor of elastase significantly diminishes the 
extent of elastase-induced emphysema [Kleinerman et al .. 
Am. Rev. Resir. Dis. 121. 381-387 (1980); Lucey et al .. Eur. 
Respir. J. 2. 421-427 (1989); incorporated herein by 
reference]. Thus the novel inhibitors described here should 25 
be useful for the treatment of emphysema and inflammation. 
Elastase inhibitors have been used orally, by injection. or by 
instillation in the lungs in animal studies (Powers, Am. Rev. 
Respir. Dis., 127. s54-s58 (1983); Powers and Bengali, Am. 
Rev. Respir. Dis. 134. 1097-1100 (1986); these two articles 30 
are incorporated herein by reference). The inhibitors 
described above can be used by any of these routes. 
Drug Delivery. For therapeutic use, the peptide 
cx-ketoamides may be administered orally. topically or 
parenterally. The term parenteral as used includes subcuta- 35 
neous injection, intravenous, intramuscular, intrasternal 
injection or infusion techniques. The dosage depends pri-
marily on the specific formulation and on the object of the 
therapy or prophylaxis. The amount of the individual doses 
as well as the administration is best determined by individu- 40 
ally assessing the particular case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use. for 
example as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or granules, emulsions, 45 
hard or soft capsules or syrups or elixirs. Dosage levels of 
the order to 0.2 mg to 140 mg per kilogram of body weight 
per day are useful in the treatment of above-indicated 
conditions (10 mg to 7 gms per patient per day). The amount 
of active ingredient that may be combined with carrier 50 
materials to produce a single dosage form will vary depend-
ing upon the host treated and the particular mode of admin-
istration. 
SYNI'HEI'IC METHODS 
The a-ketoamide inhibitors are prepared from the corre-
sponding a-ketoamide. The ketoester inhibitors are prepared 
by a two step Dakin-West from the corresponding peptide 
acid (Charles et al .. J. Chem. Soc. Perkin 1, 1139-1146. 
1980). This procedure can be utilized with either amino acid 
derivatives, dipeptide derivatives. tripeptide derivatives. or 
tetrapeptide derivatives as shown in the following scheme. 
M 1-AA---OH--+Enol Ester--+M1-AA-CO---O-R 
M 1-AA-AA---OH--+Enol Ester--+M1-AA-AA-CO-O-R 
M 1-AA-AA-AA---0H--+Enol Ester--+M1-AA-AA-AA-
CO---O-R 
M 1-AA1-AA2-AA3-AA4 ---0H--+Enol Ester--+M1-AA1-
AA2-AA3-AA4-CO-O-R 
The precursor peptide can be prepared using standard pep-
tide chemistry which is well described in publications such 
as The Peptides, Analysis, Synthesis, Biowgy, Vol. 1-9, 
published in 1979-1987 by Academic Press and Houben-
Weyl Methoden der Organischen Chemie. Vol. 15, Parts 1 
and 2. Synthese von Peptiden, published by Georg Thieme 
Verlag, Stuttgart in 197 4 (both references incorporated 
herein by reference). 
The M 1 group can be introduced using a number of 
different reaction schemes. First it could be introduced 
directly on an amino acid as shown in the following scheme 
(top), or the M1 group could be introduced by reaction with 
an amino acid ester, followed by removal of the ester group 
to give the same product (bottom). 
H-AA---0H--+M1-AA---OH 
H-AA---OR'--+M1-AA---OR'--+M1-AA---OH 
The techniques for introduction of the M1 group is well 
documented in the The Peptides. Houben-Weyel, and many 
other textbooks on organic synthesis. For example reaction 
with cyanate or p-nitrophenyl cyanate would introduce a 
carbamyl group (M 1 =NH 2 CO-). Reaction with 
Me2NCOC1 would introduce the Me2NCO- group. Reac-
tion with p-nitrophenyl thiocarbamate would introduce a 
thio carbamyl group (M1=NH2CS-). Reaction with 
NH2S02Cl would introduce the NH2S02- group. Reaction 
with Me2NS02Cl would introduce the Me2NS02- group. 
Reaction with a substituted alkyl or aryl isocyanate would 
introduce the X-NH-CO- group where X is a substi-
tuted alkyl or aryl group. Reaction with a substituted alkyl 
or aryl isothiocyanate would introduce the X-NH-CS-
For injection. the therapeutic amount of the peptide 
cx-ketoamides or their pharmaceutically acceptable salts will 55 
normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular or subscutaneous injection. Accordingly. pharma-
ceutical compositions for parenteral administration will con-
tain in a single dosage form about 10 mg to 7 gms of the 60 
compounds per dose. In addition t6 the active ingredient. 
these pharmaceutical compositions will usually contain a 
buffer. e.g. a phosphate buffer which keeps the pH in the 
range from 3.5 to 7 and also sodium chloride, mannitol or 
sorbitol for adjusting the isotonic pressure. 65 group where Xis a substututed alkyl or aryl group. Reaction 
with X--S02-Cl would introduce the X--S02- group. 
Reaction with a substituted alkyl or aryl acid chloride would 
A composition for topical application can be formulated 
as an aqueous solution, lotion, jelly or an oily solution or 
5,763,576 
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introduce an acyl group (M=X-CO-). For example. reac-
tion with Me0-CO-CH2CH2-CO-Cl would give the 
X-CO- group where Xis a C2 alkyl substituted with a Cl 
alkyl-OCO- group. Reaction with a substituted alkyl or 
aryl thioacid chloride would introduce a thioacyl group 
(M=X-CS-). Reaction with an a substituted alkyl or aryl 
sulfonyl chloride would introduce an X-S02- group. For 
example reaction with dansyl chloride would give the 
X-S02- derivative where X was a naphthyl group mono 10 
substituted with a dimethylamino group. Reaction with a 
substituted alkyl or aryl chloroformate would introduce a 
X-0--CO- group. Reaction with a substituted alkyl or 
aryl chlorothioformate would introduce a X-0-CS-. 
There are many alternate reaction schemes which could be 15 
used to introduce all of the above M 1 groups to give either 
M1-AA-OH or M 1-AA-OR-. 
The M1-AA-OH derivatives could then be used 
directly in the Dakin-West reaction or could be converted 
into the dipeptides. tripeptides. and tetrapeptides 20 
M 1-AA-AA-OH. Mi-AA-AA-AA-OH. or 
Mi-AA1-AA2-AA3-AA4-0H which could be be 
used in the Dakin-West reaction. The substituted peptides 
M 1-AA-AA-OH. Mi-AA-AA-AA-OH. or 25 
M1-AA1-AA2-AA3-AA4-0H could also be pre-
pared directly from H-AA-AA-OH. H-AA-AA-
AA-OH. or H-AA1-AA2-AA3-AA4--0H using the 
reactions described above for introduction of the M 1 group. 
Alternately. the M1 group could be introduced by reaction 
with carboxyl blocked peptides to give M1-AA-AA-
OR-, M 1-AA-AA-AA-OR-. or M 1-AA1-
AA2-AA3-AA4-0R-, followed by the removal of the 
blocking group R'. 
30 
22 
Most of the aspartyl a-keto amides (12-15, 24-36) were 
synthesized by an adaption of the strategy of Wasserman et 
al. (Scheme 1 and 2) [Wasserman. H. H. and Ho. W.-B .. J. 
Org. Chem. 59. 4364-4366 (1994) incorporated herein by 
reference]. The mixed anhydride of a protected L-aspartic 
acid derivative (2-4) was added to the cyanophosphorane 
The R group in the ketoester structures is introduced 
during the Dakin-West reaction by reaction with an oxalyl 
chloride Cl-CO-CO-O-R. For example, reaction of 
M1-AA-AA-OH with ethyl oxalyl chloride 0-CO-
CO-O-Et gives the keto ester M 1-AA-AA-C0-
0-Et. Reaction of M 1-AA-AA-AA-AA-OH with 
Cl-CO-C0-0-Bzl would give the ketoester 
M1-AA-AA-AA-AA-CO-O-Bzl. Oearly a wide 
variety of R groups can be introduced into the ketoester 
structure by reaction with various alkyl or arylalkyl oxalyl 
chlorides (Cl-CO-CO-O-R). The oxalyl chlorides are 
easily prepared by reaction of an alkyl or arylalkyl alcohol 
with oxalyl chloride Cl-CO-CO-Cl. For example. 
Bzl-0--CO-CO-CI and n-Bu-0-CO--CO-Cl are 
prepared by reaction of respectively benzyl alcohol and 
butanol with oxalyl chloride in yields of 50% and 80% 
[Warren, C. B .• and Malee, E. J., J. Chromatography 64, 
219-222 (1972); incorporated herein by reference]. 
35 generated in situ from the corresponding phosphonium 
bromide (1) [Hamper. B. C .. J. Org. Chem. 53. 5558-5562 
(1988) incorporated herein by reference]. The aspartylphos-
phorane (5-7) was then ozonolyzed at -78° C. and the 
highly reactive dicarbonylnitrile intermediate was treated 
40 
with the appropriate amine to generate the a-keto amide 
(8-11). Removal of the benzyl ester by hydrogenation in the 
presence of Pearlmann's catalyst or by stirring the a-keto 
amide in trifluoroacetic acid gave the aspartyl a-keto amide 
45 inhibitors 12-14 and 15 respectively. Alternatively. the Boe 
group was removed using HCl gas in ethyl acetate (Scheme 
2) and the deprotected amines (22. 23) were either hydro-
genated to give the unprotected aspartyl a-keto amides (24. 
25) or coupled with a variety of acids, followed by hydro-
50 genation to give the required inhibitors (26-36). 
Scheme 1. 
Ketoamides Mi-AA-CO-NR3R4, M-AA-AA-
CO-NR3R4. M-AA-AA-AA-CO-NR3R4, 
55 
M-AA-AA-AA-AA-CO-NR3R4 were prepared 
indirectly from the ketoesters. The ketone carbonyl group 
was first protected as shown in the following scheme and 
then the ketoamide was prepared by reaction with an amine 60 
H-NR3~. The illustrated procedure should also work with 
other protecting groups. In addition, the corresponding 
ketoacid could be used as a precursor. Blocking the ketone 
carbonyl group of the ketoacid and then coupling with an 
amine H-NR3R4 using standard peptide coupling reagents 
would yield an intermediate which could then be deblocked 
BtCH-r>N + P""'- benzene > BrPh PCH CN 
'L'-' u" reflux a 2 
to form the ketoamide. 
2 R1=Boc, Ri=Bzl 
65 3R1:Cbz,R2=t·B~ 4 R1 - MeOCO, Ri - Bzl 
1 
5 Rt= Boe, R1=Bzl 
6 Rt= Cbz, R1 = t-Bu 
7 Rt= MeOCO, R2 = Bzl 
23 
-continued 
Scheme 1. 
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8,9, 11 
24 
-continued 
Scheme 1. 
12 R1=Boc, 
0 
OH 
0 
8 Rt= Boe, R1 = Bzl. 
15 
R1 = CH2CHiPh 
13 R1=Boc, 
RJ = CH2CHiPh R1 = CH2CHiCHiPh 
9 Rt= Boe, Rz= Bzl, 
RJ = CH2CH2CHiP 
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28 RJ = CHiCHiPh, 14 = PhCHiCHiCO-Ala-Ala 
29RJ=CHiCH2Ph,14= PhCHiCHiCO-Val-Gly 
31 R1 = CHiCH2Ph, 14= PhCHiCHiCO-Val-Ala 
33RJ=CH2CH2Ph,14= p-Cl-PhCHiCH2CO-Val-Ala 
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15 
24 R1 = CHiCH2Ph 
25 R1 = CHiCH2CH2Ph 
Four of the peptidyl a-keto amides (54-57) were prepared 
by an alternative method (Scheme 3) [ Gmeiner. P., Junge. D. 
& Kartner. A. J. Org. Chem 59. 6766--0776 (1994) incor-
porated herein by reference). Aspartic acid was benzylated 
to give (37) followed by reduction to the cliol derivative 38. 
5,763,576 
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The C-4 alcohol was selectively protected as the dimethyl 
t-butylsilyl ether (39) and the C-1 alcohol was oxidized to 
the aldehyde (40). After stirring in neat 
trimethylsilylcyanide. the cyanohydrin (41) was hydrolyzed 
and the crude intermediate was coupled to the appropriate 5 
amine to give a dihydroxy amide (42. 43). After debenzy-
lation in the presence of Pearlmann's catalyst. the dihy-
droxyamine (44. 
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55 45) was coupled with the required acid to give the corre-
sponding peptidyl dihydroxy amide (4~9). Several 
attempts at directly oxidizing the dihydroxy amide to the 
final a-keto amide product were not successful. Mild to 
strong basic oxidation conditions produced mostly the start-
60 ing diol, byproducts such as the dehydrated aldehyde or 
cyclized lactone, mixed with the desired a-keto amide. 
Under mild acidic oxidation conditions (chromic acid). the 
starting diol and the lactone were obtained. Under strong 
acidic oxidation conditions (Jones reagent) only decom-
65 posed products were obtained. Thus, it was necessary to 
oxidize the primary and secondary alcohols separately. 
Therefore, the primary alcohol was protected again (50-53) 
5,763,576 
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and the final form of the cx-keto amide was obtained by a 
consecutive double oxidation where the silyl protecting 
group was simultaneously removed at the second oxidation 
stage with chromic acid in acetic acid. 
The peptide acids (Re-OH in Scheme 2 and R2-0H in 5 
Scheme 3) were prepared for the most part by standard 
peptide coupling methods. 
The following detailed examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
28 
C26H33N30 5 : 467.56; C. 66.79; H. 7.11; N.8.99; found: C, 
66.59; H. 7.09; N. 8.95. NMR (CDC13) ok. MS (FAB) 
m/e=468 (M+l). 
EXAMPIB 2 
Z-Leu-Phe-CONH-nPr 
EXAMPLE 1 
Z-Leu-Phe-CONH-Et 
To a stirred solution of Z-Leu-Phe-OH (20 g. 48.5 
mmole ). 4-dimethylaminopyridine (0.587 g. 4. 8 mmole ),and 
pyridine (15.7 ml. 194 mmole) in anhydrous THF (100 ml) 
was added ethyl oxalyl chloride (11.4 ml. 101.8 mmole) at 
This compound was synthesized from the protected 
cx-ketoester and propylamine in 92% yield by the procedure 
10 described in Example 1. Single spot on TLC. R_t=0.50 
(CHC1;/CH30H 50:1); mp 152°-153° C. Anal. calcd. for 
C27H35N30 5 : 481.57; C. 67.33; H. 7.33; N. 8.72. Found: C. 
67.21; H. 7.38; N. 8.64. NMR (CDC13 ) ok. MS (FAB) 
m/e=482 (M+l). 
15 
a rate sufficient to initiate refluxing. The mixture was gently 
refluxed for 4 hours. cooled to room temperature. and water 
(80 ml) was added. The reaction mixture was stirred vigor- 20 
ously for 30 min. and extracted with ethyl acetate (3-100 
ml). The combined organic layers were washed with water 
(2-100 ml), saturated sodium chloride (2x100 ml). decol-
orized with decolorizing carbon. dried over magnesium 
sulfate. and concentrated. leaving a dark orange oil. Chro- 25 
matography on a silica gel column with CHC1:/CH30H (50:1 v/v) afforded 14.63 g (y=53%) of Z-Leu-Phe-
enolester. The product was a yellow oil. Single spot on 1LC. 
P.j=-0.77 (CHCL:/CH30H 50:1). NMR (CDC13 ) ok. 30 
To a stirred pale yellow solution of the Z-Leu-Phe-
enolester (14.63 g. 25.73 mmole) in anhydrous ethanol (50 
ml) was added a solution of sodium ethoxide (0.177 g. 2.6 
mmole) in ethanol (5 ml). The orange solution was stirred 
EXAMPIB 3 
Z-Leu-Phe-CONH-nBu 
This compound was synthesized from the protected 
a-lretoester and butylamine in 67% yield by the procedure 
described in Example 1. Single spot on 1LC, R_t=0.50. 
(CHCly1CH30H 50:1); mp 152°-153° C. Anal. calcd. for 
C28H37N30 5 : 495.59; C. 67.85; H. 7.52; N. 8.48. Found: C. 
67.70; H. 7.57; N, 8.43. NMR (CDC13) ok. MS (FAB) 
m/e=496 (M+l). 
EXAMPIB4 
Z-Leu-Phe-CONH-iBu 
This compound was synthesized from the protected 
cx-lretoester and isobutylamine in 53% yield by the proce-
dure described in Example 1. Single spot on 1LC. R_t=0.54 
(CHC1;/CH3 0H 50:1); mp 152° C. Anal. calcd. for 
35 C28H37N30 5 : 495.59; C. 67.85; H. 7.52; N, 8.48. Found: C. 
67.77; H. 7.56; N. 8.40. NMR (CDC13) ok. MS (FAB) 
m/e=496 (M+ 1 ). 
for 3 hours at room temperature, then the ethanol was 
evaporated and the residue was treated with ethyl ether (300 
ml). The ether layer was washed with water (2-100 ml). 
saturated sodium chloride (2-100 ml). dried over magne-
sium sulfate, and concentrated, leaving a orange oil. Chro-
matography on a silica gel column with CHC}iCH30H 40 (50:1 v/v) afforded 7.76 g (y=64%) of the a.-lretoester 
Z-Leu-Phe-COOEt. The product was a yellow oil. 
EXAMPLES 
Z-Leu-Phe-CONH-Bzl 
Single spot on 1LC. R_t=0.44 (CHC1/CH30H 50: 1). NMR This compound was synthesized from the protected 
(CDC13) ok. MS (FAB. calcd. for C2~32N206 : 468.6). a-lretoester and benzylamine in 40% yield by the procedure 
m/e=469 (M+l). 45 described in Example 1. After reacting overnight. ethyl 
The ex-carbonyl group of Z-Leu-Phe-COOEt was acetate (60 ml) was added. The mixture was filtered to 
protected by the following procedure. To a solution of remove a white precipitate. The solution was washed with 
Z-Leu-Phe-COOEt (1 g. 2.13 mmole) in 5 ml of cooled lN HCl (3-25 ml), water (l-20 ml), saturated 
CH2Cl2 was added 1.2-ethanedithiol (0.214 ml. 2.55 sodium chloride (2-20 ml), and dried over magnesium 
mmole), followed by 0.5 ml of boron trifluoride etherate. 50 sulfate. The solution was evaporated leaving a yellow solid. 
The solution was stirred overnight at room temperatme. Chromatography on a silica gel column with CHC13'CH30H 
Water (20 ml) and ethyl ether (20 ml) were added. The 30:1 v/v) afforded a yellow solid. Single spot on 1LC. 
organic layer was separated, washed with water (2-10 ml). R_t=0.45 (CHCly1CH30H 30:1); mp 160°-162° C. Anal. 
saturated sodium chloride (2-10 ml). dried over magnesium calcd. for C31H35N30 5 : 529.61; C, 70.30; H. 6.66; N. 7.93. 
sulfate. and evaporated to afford 0.98 g (y=84%) yellow 55 Found: C. 70.18; H. 6.67; N, 7.99. NMR (CDC13 ) ok. MS 
semisolid. (FAB) m/e=530 (M+l). 
The protected a-lretoester (0.98 g, 1.8 mmole) was dis-
solved in ethanol (5 ml). cooled to 0°-5° C. in an ice bath, 
and ethylamine was bubbled through the solution until 2.43 
g (54 mmole) had been added. The reaction mixture was 60 
allowed to warm to room temperature slowly. and stirred 
overnight. The mixture was filtered. a white precipitate was 
removed, leaving a yellow semisolid. Chromatography on a 
silica gel column with CHCly1CH30H (30: 1 v/v) afford 0.63 
g (y=75%) of Z-Leu-Phe-CONH-Et. The product was 65 
a pale yellow solid. Single spot on 1LC, R.f=0.60 (CHC13' 
CH30H 20:1); mp 145°-147° C. Anal. calcd. for 
EXAMPIB6 
Z-Leu-Phe-CONH-{CH2)2Ph 
This compound was synthesized from the protected 
a-lretoester and phenethylamine in 50% yield by the pro-
cedure described in Example 5. Single spot on TLC. R_t=0.50 
(CHC1:/CH30H 30:1); mp 151°-153° C. Anal. calcd. for 
C32H37N30 5 : 543.66; C. 70.70; H. 6.86; N, 7.73. Found: C. 
70.54; H. 6.88; N. 7.74. NMR (CDC13) ok. MS (FAB) 
m/e=544 (M+l). 
29 
EXAMPLE7 
Z-Leu-Abu--CONH-Et 
5,763.576 
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EXAMPLE13 
This compound was synthesized from protected 
5 
cx-ketoester derived from Z-Leu-Abu-CO:zEt and ethy-
This compound was synthesized from protected 
a-ketoester and 4(3-aminopropyl)morpholine in 33% yield 
by the procedure described in Example l. After reacting 
overnight. ethyl acetate (80 ml) was added. The mixture was 
filtered to remove a white precipitate. The solution was 
larn.ine in 64% yield by the procedure described in Example 
1. Single spot on TLC. iy:o.36 (CHCl/CH30H 50;1); mp 
130°-132° C. Anal. calcd. for C21 H31Np5 : 405.45; C, 
62.20; H, 7.71; N.10.36. Found: C. 61.92; H. 7.62;N.10.31. 
NMR (CDC13 ) ok. MS (FAB) m/e=406 (M+l). lO 
washed with water (3-20 ml), saturated sodium chloride 
(2-20 ml). and dried over magnesium sulfate. The solution 
was evaporated leaving a yellow oil. Chromatography on a 
EXAMPLE 8 
Z-Leu-Abu--CONH-nPr 
silica gel column with CHC1/CH30H (10: 1 v/v) afforded 
a yellow semisolid. which was recrystallized from ethyl 
15 
acetate/hexane to obtain a pale yellow solid. Single spot on 
TLC. Rr0.42 (CHC1/CH30H 10:1); mp 125°-126° C. 
Anal. calcd. for C26H4oN40 6 : 504.63; C. 61.88; H. 7.99; N, 
11.10. Found: C. 61.69; H. 7.95; N, 11.07. NMR (CDC13 ) 
ok. MS (FAB) m/e=505 (M+l). 
This compound was synthesized from the corresponding 
protected cx-ketoester and propylamine in 47% yield by the 
procedure described in Example 1. Single spot on TLC. 
R.t=0.28 (CHC1/CH30H 50:1); mp 134°-135° C. Anal. 
calcd. for C22H33N30 5 : 419.50; C, 62.98; H. 7.93; N, 10.02. 20 
Found: C. 62.84; H. 7.97; N. 9.94. NMR (CDC13 ) ok. MS 
(FAB) m/e=420 (M+l). 
EXAMPLE 14 
Z-Leu-Abu-CONH-{CH2 hCH3 
EXAMPLE9 
Z-Leu-Abu--CONH-nBu 
This compound was synthesized from the corresponding 
protected cx-ketoester and butylamine in 42% yield by the 
procedure described in Example l. Single spot on TLC. 
iy:o.54 (CHC1/CH30H 50:1); mp 135°-136° C. Anal. 
calcd. for C23H35N30 5: 433.53; C. 63.71; H. 8.13; N, 9.69. 
Found: C, 63.48; H. 8.07; N, 9.67. NMR (CDC13) ok. MS 
(FAB) m/e=434 (M+l). 
EXAMPLE 10 
Z-Leu-Abu--CONH-iBu 
This compound was synthesized from the corresponding 
protected a-ketoester and isobutylamine in 65 % yield by the 
procedure described in Example 1. Single spot on TLC. 
iy:o.25 (CHC1/CH30H 50:1); mp 133°-135° C. Anal. 
calcd. for C23H3sN30 5 : 433.52; C. 63.72; H, 8.14; N. 9.69. 
Found: C. 63.46; H, 8.10; N, 9.60. NMR (CDC13 ) ok. MS 
(FAB) m/e=434 (M+l). 
EXAMPLE 11 
Z-Leu-Abu--CONH-Bzl 
This compound was synthesized from the corresponding 
protected cx-ketoester and benzylamine in 29% yield by the 
procedure described in Example 5. Single spot on TLC, 
IY=0.56 (CHC1/CH30H 30:1); mp 140°-141° C. Anal. 
calcd. for C26H33N30 5 : 467.54; C, 66.79; H. 7.11; N, 8.99. 
Found: C. 66.65; H. 7.07; N, 8.93. NMR (CDC13) ok. MS 
(FAB) m/e=468 (M+l). 
EXAMPLE 12 
Z-Leu-Abu--CONH-{CH~~ 
This compound was synthesized from the corresponding 
protected cx-ketoester and phenethylamine in 51 % yield by 
the procedure described in Example 5. Single spot on TLC, 
iy:o.44 (CHC1/CH30H 30:1); mp 156°-157° C. Anal. 
calcd. for C27H35N30 5 : 481.59; C, 67.34; H. 7.33; N, 8.72. 
Found: C. 67.38; H. 7.33; N, 8.78. NMR (C003 ) ok. MS 
(FAB) m/e=482 (M+l). 
This compound was synthesized from the corresponding 
25 protected cx-ketoester and octylamine in 67% yield by the 
procedure described in Example 5. It was white solid. Single 
spot on TLC. R.t=0.55 (CHC1/CH30H 30:1); mp 134°-135° 
C. Anal. calcd. for C27H43N 30 5 : 489.66; C. 66.23; H, 8.85; 
N. 8.58. Found: C. 66.19; H. 8.81; N, 8.61. NMR (CDC13 ) 
30 ok. MS (FAB) m/e=490 (M+l). 
35 
EXAMPLE 15 
Z-Leu-Abu-CONH-{CH2)iOH 
This compound was synthesized from the corresponding 
protected a-ketoester and ethanolamine in 29% yield by the 
procedure described in Example 13. The product was a 
white sticky solid. Single spot on TLC. Rr0.42 (CHCl/ 
CH30H 10:1); mp 151°-153° C. Anal: calcd. for 
40 C21H31N 30 6 : 421.49; C, 59.84; H. 7.41; N, 9.97. Found: C. 
59.11; H. 7.44; N, 9.81. NMR (CDC13 ) ok. MS (FAB) 
m/e=422 (M+l). 
45 
EXAMPLE 16 
Z-Leu-Abu-CONH-{CH~20(CH~20 H 
This compound was synthesized from the corresponding 
protected a-ketoester and 2-(2-aminoethoxy)ethanol in 34% 
50 yield by the procedure described in Example 13. The prod-
uct was white sticky solid. Single spot on TLC. IY=0.42 
(CHC}iCH30H 10:1); mp 103°-105° C. Anal.: calcd. for 
C23H35N3Q7 : 465.55; C, 59.34; H. 7.58; N, 9.03. Found: C. 
59.23; H. 7.58; N, 9.01. NMR (CDCl3 ) ok. MS (FAB) 
55 m/e=466 (M+l). 
EXAMPLE 17 
Z-Leu-Abu-CONH-{CH~17CH3 
60 This compound was synthesized from the corresponding 
protected cx-ketoester and octadecylamine in 12% yield by 
the procedure described in Example 5. The product was a 
pale yellow solid. Single spot on TLC. iy:o.54 (CHCl/ 
CH 30H 30:1); mp 134°-136° C. Anal: calcd. for 
65 C37H63N30 5 : 629.92; C. 70.55; H.10.08; N. 6.67. Found: C. 
70.71; H, 10.14; N. 6.75. NMR (CDC13) ok. MS (FAB) 
m/e=630.2 (M+l). 
5,763.576 
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EXAMPLE 18 
Z-Leu-Abu-CONH-CH2-C6H3(0CH3)2 
32 
-15° C. for 5 min before being added dropwise with stirring 
to the previously prepared cyanomethylphosphorane solu-
tion. The mixture was stirred at 0° C. for 15 min and then 
allowed to warm to room temperature and then stirred for a This compound was synthesized from the corresponding 
protected ex-ketoester and 3.5-dimethoxybenzylamine in 
45% yield by the procedure described in Example 5. The 
product was yellow sticky solid. Single spot on 1LC. 
R_,=0.44 (CHC1/CH30H 30:1); mp 153°-155° C. Anal.: 
calcd. for C28H37N30 7: 527.62; C. 63.74; H. 7.07; N. 7.96. 
Found: C. 63.66; H. 7.09; N, 7.92. NMR (CDC13) ok. MS 
(FAB) mle=528.8 (M+l). 
5 further 16 h. The precipitate was removed by filtration and 
the solvent removed under reduced pressure. The mixture 
was purified by chromatography on silica gel (0-50% ethyl 
acetate in hexane) to yield the product as a clear oil which 
solidified on drying (0.76 g. 70%): mp 42°-44° C.; 1H NMR 
EXAMPLE 19 
10 (CDC13) ol.39 (s. 9H, Boe CH3's), 2.99 (d. 2H. ~H2). 
5.06 (m, 3H. ex-CH & benzyl CH2 ), 5.62 (d. lH. NH), 7.28 
(m. 5H. benzyl aromatic CH's). 7.52 (m. lSH. PPh3 aro-
matic CH's); MS (EL calculated for C36H35N20 5P. 
606.2284) mle 606.2292 (M+). 
This compound was synthesized from the corresponding 
protected ex-ketoester and 4-(arninomethyl)pyridine in 45% 
yield by the procedure described in Example 13. The prod-
15 
uct was greenish yellow solid. Single spot on 1LC. R_r().55 20 
(CHCIJCH30H 10:1); mp 124°-126° C. Anal: calcd. for 
C25H32N40 5: 468.55; C. 64.08; H. 6.88; N. 11.%. Found: C. 
63.88; H. 6.87; N. 11.96. NMR (CDC13) ok. MS (FAB) 
mle=469 (M+l). 
5-Cyano-5-triphenylphosphoranylidene-4-keto-3-(N-
benzyloxylcarbonylarnino)pentanoic Acid t-Butyl 
Ester (6) 
This was synthesized in a manner identical to that used for 
5. except that N-benzyloxycarbonyl-13-t-butyl aspartic acid 
(3. 4.01 g. 12.4 mmol) was used instead of N-t-
butyloxycarbonylaspartic acid 13-benzyl ester (2. Boe-Asp 
(Bzl)--OH) to give the product as pale yellow tlakes (4.70 
g. 7.74 mmol. 62% yield) after purification by silica gel 
Methods and Starting Materials 25 chromatography (R_r().43, Et0Ac:hexane=2:1): 
1H NMR 
(DMSO-~) ol.35 (s. 9H. Boe CH3's), 2.39 (dd, lH. 
~H2). 2.69 (dd. lH. 13--CH2 ), 5.04 (m. 3H. a-CH & 
benzyl CH2). 7.33 (m. 5H, benzyl aromatic CH's). 7.65 (m, 
Unless otherwise noted. materials were obtained from 
commercial suppliers and used without further purification. 
The purity of each compound was checked by 1LC. mp. 1 H 
NMR and mass spectroscopy. 1LC were performed on 30 
Baker Si250F silica gel plates. Melting points were obtained 
on a Biichi capillary apparatus and are not corrected. 1 H 
NMR spectra were determined on a Varian Gemini 300. 
Chemical shifts are expressed in ppm relative to internal 
tetramethylsilane. Mass spectra were obtained on a Varian 35 
15H. PPh3 aromatic CH's). 7.80 (m. lH. NH); FABMS 
(calculated for C36H3~205P. 607.2362) mle 607.2355 (M++l). 
5-Cyano-5-triphenylphosphoranylidene-4-keto-3-(N-
methyloxylcarbonylarnino )pentanoic Acid Benzyl 
Ester (7) 
MAT 112S spectrometer. Column chromatography was per- This was synthesized in a manner identical to that used for 
formed on silica gel (32°-63 microns). 5. except that methyloxycarbonylaspartic acid 13-benzyl 
The physical properties and proton NMR data for the ester (4, 506 mg. 1.8 mmol) instead of 2 to give the product 
peptide ex-keto amide inhibitors are given in Tables m and 
40 
as a clear oil which was recrystallized from ether/hexane 
IV repectively. (447 mg. 44%): 1H NMR (CDC13) 03.00 (m. 2H. ~H2), 
Triphenyl Cyanomethyl Phosphonium Bromide (1) 3.57 (s, 3H, CH30). 5.05 (s, 2H. benzyl CH2). 5.11 (m. lH. 
[ vik S d S kh G ex-CH), 5.85 (d, lH. NH). 7.23 (m. SH, benzyl aromatic No ov, . S. an hve geimer. .A. Izvest.Akad. Nauk CH' ) 7 48 ( lSH PPh · CH' )· FABMS S.S. R.R .. Otdel. Khim. Nauk. 2061-2063 (1960) incorpo- s • · m. • 3 aromatic s • 
rated herein by reference]. A solution of bromoacetonitrile 45 ((::cui)ated for C33H3oN20,P. 565.1892) mle 565.1891 (6.07 g. 50 mmol) and triphenyl phosphine (16.07 g. 60 + · 
mmol) in 50 mL of benzene was refluxed under an argon 
atmosphere for 30 minutes. After cooling to room 
temperature, the product was collected by filtration and 
dried under reduced pressure to give 16.51 g ( 43 mmol. 86% 50 
yield) of a white powder: 1H NMR (DMSO-d6) 05.81 (cl 
2H. P-C_!!z-CN). 7.86 (m. 12H. aromatic). 8.00 (m, 3H. 
aromatic); FABMS (calculated for C20H17NP. 302.1099) 
mle 302.1097 (M+-HBr+ l ). 
EXAMPLE20 
Ozone gas was bubbled through a solution of 5 (606 mg. 
l mmol) in CH2Cl2 (20 mL) cooled to -78° C. until its blue 
color persists within the solution. The excess ozone was 
purged using argon and phenethylamine (181 mg. 189 µL, 
1.5 mmol) was added. The resulting solution was stirred at 
5-Cyano-5-triphenylphosphoranylidene-4-keto-3-(N-
t-butyloxylcarbonylamino)pentanoic Acid Benzyl 
Ester (5) 
55 - 78° C. for 1 h and then allowed to warm to r.t The solvent 
was removed under reduced pressure and the residue chro-
matographed on silica gel (0-30% ethyl acetate in hexane) 
to yield the product as a clear oil which was then recrystal-
To a suspension of triphenyl cyanomethyl phosphonium lized from ether/hexane (145 mg. 32%): mp 132°-134° C.; 
bromide (1. 0.68 g. 1.8 mmol) in anhydrous THF (10 mL) 60 1H NMR (CDCI3) ol.43 (s. 9H. Boe CH3 's). 2.81 (t. 2H. 
cooled in an ice bath was added triethylamine (3% mg. 546 NHCH2-CH2-Ph). 3.12 ( dd, lH. 1 of CH2-C02Bzl). 
µL. 3.9 mrnol) and the mixture stirred in an ice bath for 15 3.44 (dd. lH. 1 of CH2-C02Bzl), 3.55 (t. 2H. NH-CH2-
min. To a solution of N-t-butyloxycarbonyl-~- CH2Ph). 5.10 (s. 2H. benzyl CH2). 5.13 (m. lH, ex-CH). 
benzylaspartic acid (2. 575 mg, 1.8 mmol) in THF (15 mL) 5.51 (d, lH, urethane NH). 6.92 (br. lH. amide NH). 7.20 
cooledto-15° C. wasaddedN-methylmorpholine(l80mg. 65 (m. 5H. phenethyl aromatic CH's), 7.30 (m. 5H. benzyl 
196 µL. 1.8 mmol) followed by iso-butylchloroformate (243 aromatic CH's); FABMS (calculated for C2~H31N206• 
mg. 231µL,1.8 mmol). The resulting solution was stirred at 455.2182) mle 455.2146 (M++l). 
5,763.576 
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EXAMPLE21 
34 
filtered through Celite and the solvent removed under 
reduced pressure to yield 1.82 g (9.8 mmol, 98%) of a white 
solid: mp. 103°-105° C.; 1H NMR (DMSO-~) 02.51(t.2H. 
j3---CH2). 2.79 (t, 2H. (a-CH2). 7.28 (dd. 4H. aromatic 
5 CH's). 12.12 (s. lH. COOH); MS (EI. calculated for 
~~Cl02. 184.0291) rnle 184.0288 {W). 
This was prepared in a manner identical to that for 8. 
except using 3-phenyl-1-propylamine (203 mg. 213 µL. 1.5 
mmol) instead of phenethylamine to yield the product as a 
white crystalline solid (117 mg. 25%): mp 87°-88° C.; 1H 
NMR (CDC13): 1.45 (s. 9H. Boe CH3 's). 1.81 (tt. 2H. 
NHCH2-CH2-CH2Ph). 2.63 (t. 2H. NHCH2CH2-
CH2-Ph), 2.70 (dd. lH. 1ofCH2-C02Bzl).3.05 (dd. lH. 10 
1 of CH2-C0i13zl). 3.27 (t. 2H. NH-CH2-CH2CH)>h). 
4.48 (m. lH. a-CH). 5.11 (s. 2H, benzyl CH2). 5.65 (br. 
lH. urethane NH), 6.49 (br. lH, amide NH). 7.28 (m. lOH. 
aromatic CH's); FABMS (calculated for C26H33N20 6 • 
469.2339) rnle 469.2359 (M++l). 
EXAMPLE22 
Cbz-Asp(t-Bu)-CONH-CH2CH2Ph (10) 
This was prepared in a manner identical to that used for 
EXAMPLE26 
HCl.H-Asp-CONH-CH2CHj>h (24) 
The keto amide (8) (227 mg. 0.5 mmol) was dissolved in 
ethyl acetate ( 10 mL) and cooled in an ice bath. Dry HCl gas 
was bubbled through until the solution was saturated and 
then the solution was stirred at r.t. until the starting material 
15 had been consumed as indicated by tlc (-30 min). The 
solvent was removed under reduced pressure to give 
HCl.H-Asp(Bzl)-CONH-CH2CH2Ph (22) as a white 
solid: FABMS (calculated for C2off23N20 4 • 355.1658) rnle 
355.1651 (W+l-HCl). Without further purification. this 
20 crude product was used for the debenzylation reaction in a 
same manner as described for 12 to give 12 mg (0.04 mmol. 
8%) of a white solid after recrystallization from methanol/ 
ether. 
8. except using 6 (2.53 g, 4.17 mmol) instead of 5 to give the 
product as a white crystalline solid (433.8 mg. 0.95 mmol. 
22% yield) after purification by silica gel chromatography 
<RJ=0.21. EtOAc: hexane=1:3) and recrystallization from 25 
ethyl acetate and hexane: mp 89°-90° C.; 1H NMR (CDC13 ) 
EXAMPLE27 
ol.37 (s, 9H, t-Bu CH3 's). 2.83 (t, 2H, NHCH2-CH2- HC1.H-Asp-CONH-CH2CH2CH2Ph (25) 
Ph). 2.99 (dd. lH. 1 of J}-CHz). 3.39 (dd. lH, 1 of . . . . 
J}-CH2). 3.56 (q. 2H, NH-CH2-CH2Ph). 5.08 (m. lH. :nus was prepared 1Il a manner .identical to 24 except 
a-CH), 5.12 (s. 2H. benzyl CH2). 5.75 (d. lH, urethane 30 usmg 234 mg (0.5 mmol) of 9 to give 15 mg (0.05 mmol. 
NH), 6.98 (t. lH. amide NH), 7.29(m.10H. aromatic CH's); 10%) of the product. 
FABMS (calculated for C25H31N20 6 , 455.2182) rnle 
455.2201 (W+l). 
EXAMPLE23 35 
EXAMPLE28 
The keto amide (8) (109 mg. 0.24 mmol) was dissolved in 
General Procedure for the Debenzylation of ethyl acetate (5 mL) and cooled in an ice bath. Dry HCl gas 
Aspartyl f3-Benzyl Ester was bubbled through until the solution was saturated and 
D · · y- ld 12 14 24 36 (B A then the solution was stirred at r.t. until the starting material envattves to ie - • . - oc- sp- 40 had been consumed as indicated by tlc (-30 min). The CONH-CH2CH2Ph. 12). To a solution of the benzyl ester solvent was removed under reduced pressure. The residue 
Boc-Asp(OBzl)-CONH-CH2CH2Ph (8. 75 mg. 0.16 (22) di l d · dry CH Cl (5 mL) d · th 1amin 1) • th 1 (5 mL) added Pd(OH) 'C (7 5 was sso ve m z z an Irie y e 
mmo m me ano . was . '1! • mg. (61 mg. 84 µL) added. The solution was then added drop-
10% w/w) and. the solution was stirred under a hydrogen wise to a solution of benzyl sulfonyl chloride (46 mg. 0.24 
atmosphei:e until no further H2 take-up ~as o~erved (-1 h). 
45 mmol) in dry CH2Cl2 (5 mL) cooled in an ice bath. The The solution was filtered through c.elite an the solvent resulting solution was allowed to stir at r.t for 16 h. It was 
removed. un~r reduced press~e to yield the product 12 as washed with lM HCI. 5% sodium bicarbonate solution and 
a clear~ which was recrystallized from methanol/ether (50 saturated brine. then dried (MgSO 4) and the solvent 
mg, 83 ). removed under reduced pressure to yield the product as a 
EXAMPLE 24 50 white solid (51 mg. 42%): mp 128°-130° C. 1H NMR 
(CDC13 ) 02.61 & 2.99 (ABX. 2H. j3---CH2). 2.86 (t, 2H. 
Cbz-Asp-CONH-CH2CHj>h (15) CH2Ph). 3.57 (m. 2H. NH-CH2). 4.74 (m. lH. a-CH). 5.14 (2 x s, 4H, benzyl CH2 's). 6.53 & 6.74 (m. 2H. NH's). 
The t-butyl ester (10. 100 mg. 0.22 mmol) in trifl.uoro- 7.29 (m. 15H. aromatic CH's); FABMS rnle 509 (W+l). 
acetic acid (5 mL) was stirred in an ice bath for 30 minutes. 55 This product was subjected to the debenzylation condi-
Trifluoroacetic acid was removed under reduced pressure, tions as described for 12 to give 10 mg (24%) of white solid. 
the crude product was recrystallized from EtOAc/hexane to 
give 76.8 mg (0.19 mmol. 87% yield) of a pale yellow solid. 
EXAMPLE25 
3-(4-Chlorophenyl)propanoic Acid (4-
Chlorohydrocinnamic Acid) 
60 
EXAMPLE29 
General Procedure for the Synthesis of 27-35 
(Ac-Tyr-Val-Ala-Asp-CONH-CH2CH2Ph. 
35 SEQ ID N0:8) 
The ketoamide (8) (227 mg. 0.5 mmol) was dissolved in 
To a solution of 1.80 g ( 10 mmol) of 4-chlorocinnamic ethyl acetate (10 mL) and cooled in an ice bath. Dry HCl gas 
acidin50mLofTHFwasaddedPd/C(l.04g,5%w/w)and 65 was bubbled through until the solution was saturated and 
the solution was stirred under a hydrogen atmosphere until then the solution was stirred at r.t until the starting material 
no further H2 take-up was observed (-1 h). The solution was had been consumed as indicated by tic (-30 min). The 
5.763,576 
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solvent was removed under reduced pressure to give 22. To 
a solution of Ac-Tyr-Val-Ala-OH (197 mg, 0.5 mmol) 
36 
beaker containing 300 mL EtiO. A saturated aqueous 
Na2S04 solution was added with stirring to the ether solu-
tion dropwise until gas evolution ceased. The resulting 
mixture was stirred for 5 minutes and then filtered. The 
in dry THF (10 ml.) and DMF (2 ml.) cooled to -15° C. was 
added N-methyl morpholine (51 mg, 55 µL. 0.5 mmol) 
followed by iso-butyl chloroformate (68 mg, 65 µL. 0.5 
mmol) and the solution stirred at -15° C. for 5 min. A 
previously prepared solution of 22 and N-methyl morpho-
line (51mg,55 µL. 0.5 mmol) in dryTHF(5 ml.) was added. 
the solution stirred at-15° C. for 15-30 min and then at r.t. 
5 solvent was removed from the filtrate with a rotary evapo-
rator. The crude residue was purified by gel chromatography 
(Et0Ac:hexane=2:1) to give 10.12 g (0.035 mole. 89%) of 
a colorless oil: R_;=0.27 (Et0Ac:hexane=l:4); 1H NMR 
(CDC13 ) ol.45 (m. lH. 13--CH). 1.96 (m. lH.13--CH). 2.90 
10 (m. lH. a-CH). 3.28 (br. 2H. -OH). 3.59 (m. 8H. Ph-C 
H2-N. CH2--0H). 7.28 (m. lOH. aromatic H). MS (CL 
calculated for C18H24N02• 286.1807) mle 286.1843 (M++ 
1). 
for 16 h. The solution was filtered and the solvent removed 
under reduced pressure to yield the product which was 
recrystallized from methanol/ether to give 340 mg (93%) of 
Ac-Tyr-Val-Ala-Asp(Bzl)-CONH-CH2CH2Ph: 
mp 192°-194° C.; 1H NMR (DMSO) 00.77 (m, 6H. Val 
CH3 's). 1.19 (m. 3H. Ala CH3). 1.74 (s. 3H. Ac CH3). 1.93 1s 
(m. lH. Val 13--CH), 2.62 (obs. 2H. CH2Ph), 2.77 & 3.18 
(m. 4H. Tyr & Asp 13-CH2 's). 3.37 (m. 2H. NH-CH2). 
3.75. 4.09. 4.19 & 4.53 (m. 4H. a-CH's). 5.06 (s, 2H. 
benzyl CH2). 6.62 & 7.01 (2xd. 4H. Tyr aromatic CH's). 
7.20 (m. SH. phenethyl aromatic CH's). 7.35 (s. SH. benzyl 20 
aromatic CH' s). 7 .83 (m. lH. NH). 8.04 (m. 4H. NH' s). 9.15 
(s. lH. Tyr OH); FABMS m/e 730 (M++l). 
This product was subjected to the debenzylation condi-
tions as described for 12 to give 170 mg (57%) of a white 
solid. 
2-(N.N-Dibenzylamino)-4-l(t-butyldimethylsilyl) 
oxy )butanol (39) 
[Gmeiner, P .• Junge. D. and Kartner. A. J. Org. Chem. 59, 
6766-6776 (1994) incotporated herein by reference]. To a 
solution of 3.61 g (0.012 mole) of 38 in 40 mL of DMF was 
added sequentially at S° C. solutions of 2.36 g (0.016 mole) 
of t-butyldimethylsilyl chloride in 20 mL of DMF and 1.77 
g (0.026 mole) of imidazole in 20 mL of DMF. After stirring 
the resulting mixture at the same temperature for 3 hours 
under anhydrous conditions, SO mL of saturated aqueous 
25 NH4Cl solution was added and the mixture was extracted 
with Et20 (4-50 mL). The combined extracts were dried 
EXAMPLE 30 over MgS04 and filtered. The solvent was removed in vacuo 
Ac-Tyr-Val-Ala-Asp-CONH- and the crude residue was purified by gel chromatography 
cH
2
cH
2
CH)>h (36) (SEQ ID N0:8) (Et0Ac:hexane=1:5) to give 2.71 g (0.0068 mole, 56%) of 30 a colorless oil: R_;=0.31 (Et0Ac:hexane=1:4); 1H NMR 
This was prepared in a manner identical to 3S except (DMSO-~) 0-0.22 (s. 6H. Si-CH3). 0.62 [s. 9H. Si-C(C 
using (9) (234 mg. 0.5 mmol) instead of (8) to yield the H3) 3]. 1.38 (m. lH. 13--CH). 1.53 (m. lH, 13--CH). 3.17 (s. 
product which was recrystallized from methanol/ether to lH.- a-CH). 3.30 (m. 2H. -CH2--0Si-). 3.46 (m, 6H. 
give the product as a white solid. Ph-C~-N. C!!4--0H). 4.22 (t.TH. -OH). 6.98-7.16 (m. 
35 lOH. aromatic H); FABMS (calculated for C24H38N02Si. 
EXAMPLE31 
N.N-Dibenzylaspartic Acid Dibenzyl Ester (37) 
[Gmeiner, P.. Junge. D. and Kartner.A. J. Org. Chem. 59. 40 
400.2672) m/e 400.2639 (M++l). 
2-(N.N-Dibenzylamino)-4-[(t-butyldimethylsilyl) 
oxy ]butanal ( 40) 
6766-6776 (1994) incorporated herein by reference). To a [Gmeiner. P .• Junge. D. and Kartner,A. J. Org. Chem. 59, 
solution of 26.62 g (0.20 mole) of aspartic acid in 300 mL 6766-6776 (1994) incorporated herein by reference]. To a 
of 3M N~C03 was added 202 g ( 1.6 mole) of benzyl solution of 2.18 g (28 mmol) of DMSO in 5 mL of CH2Cl2, 
chloride at room temperature. The mixture was refluxed for solutions of 1.78 g ( 14 mmol) of oxalyl chloride in 5 mL of 
10 hours. After cooling to room temperature, the mixture 45 CH20 2 and 4.80 g (12 mmol) of 39 in 20 mL of CH20 2 
was extracted with ethyl acetate (2-150 mL). The combined were added sequentially at-78° C. After stirring at the same 
extracts were dried over MgS04 and then filtered. Solvent temperature under an argon atmosphere for 30 minutes. 6.07 
was removed from the filtrate with a rotary evaporator and g (60 mmol) of NEt3 in 60 mL of E!iO was added in one 
benzyl alcohol was removed at 60° C./0.5 mm Hg to yield portion. The mixture was stirred for 10 minutes. washed 
93.02 g (0.18 mole. 94%) of a light brown oil: R_;=0.74 50 with saturated aqueous NaHC03 solution (2-40 mL) and (Et0Ac:hexane=1:4); 1H NMR (CDC13) 82.82 (ddd, 2H. lM NaHS04 solution. The organic layer was dried over 
13-CH2). 3.65 (dd, 4H. Ph-CH2-N). 3.97 (t. lH. MgS04 and filtered. The solvent was removed from the 
a-CH). 5.08 (m. 4H. COO-CH2-Ph), 7.28 (m. 20H. filtrate with a rotary evaporator and the residue was dried 
aromatic H). FABMS (calculated for C32H31N04 • 493) m/e under reduced pressure to give 4.44 g (11 mmol. 93%) of a 
494 (W+l). The crude product was used for the next 55 colorless oil: R_;=0.57 (Et0Ac:hexane=1:4); 1 H NMR 
reaction without further purification. (DMSO-~) &-o.06 (s. 6H. Si-CH3), 0.76 [s. 9H. Si-C(C 
2-(N .N-Dibenzylamino )butane-1.4-diol (3 8) §).ll• 1.86 (m. 2H. ~-c~-;- 2.81 (m. 2H. -C ~--OSi-). 3.61 (m. 5H. a-CH. Ph-C§_-N). 7.28 (m. 
lOH. aromatic H). 9.70 (s, lH. aldehyde H); FABMS [Gmeiner. P .• Junge, D. and Kartner. A. J. Org. Chem. 59. 
6766-6776 (1994) incorporated herein by reference]. To a 
stirred solution of 19.40 g (0.039 mole) of 37 in 60 mL of 
anhydrous THF was added a solution of LiAlH4 in THF in 
60 (calculated for C24H3~02Si. 398.2515) m/e 398.25 lS (W+l). 
4 portions (0.46 g. 0.012 mole in 20 mL for each portion) at 
S° C. The resulting mixture was stirred at room temperature 
for 1 hour under an argon atmosphere and then allowed to 65 
stand at room temperature overnight to permit the lithium 
salt to precipitate. The organic layer was poured into a 
3-(N. N-Dibenzylamino)-5-1 (t-butyldimethylsilyl) 
oxy ]-2-[ (trimethylsilyl)oxy Jpentanenitrile ( 41) 
Amixtureof3.94 g (10 mmol) of 40and1.37 g(14 mmol) 
of trimethylsilyl cyanide was stirred at room temperature 
overnight and then dried in vacuo for 24 hours to give a 
5,763.576 
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quantitative yield of 41 as a light brown oil (racemic 
mixture): Rr0.64 (Et0Ac:hexane=1:4); 1H NMR (CDC13) 
80.078 (m. lSH. Si--CH3), 0.8S [s. 9H, Si--C(CH3) 3]. 1.87 
(m. 2H. ~2). 3.lT(m, lH. cc-CH), 3.78(iii.. 6H, 
--CH2--0Si---:- Ph--CH2-N). 4.44 [ dd, lH. --C 
!!.(CN)--OSi-J, 7.20--7.41 (m, lOH. aromatic H); FABMS 
(calculated for C28H45Np2Si2• 497.3020) m/e 497.2999 (M++l). 
N-(2-Phenylethyl)-3-(N,N-dibenzylarnino)-2,S-
dihydroxypentamide (42) 
38 
H-OH), 5.61 (d. lH. CH-OH.), 7.24 (m. lSH. aromatic 
H). 7.85 (t. lH. CON]l); FABMS (calculated for 
C28H35N20 3 • 447.2648) m/e 447.2680 ~+1). Second 
enantiomer (l.3S g, 3.0 mmol. 19% yield. a yellow oil): 
5 R.f=0.10 (Et0Ac:hexane=4:1); 1H NMR (DMSO-~) ol.73 
(m. 4H, f3---CH2. CONH-CH2--C~-CH2-Ph). 2.57 (m. 2H. C--CH;°-Ph). 3.10 (m. 4H, cc-CH, CH2--0H. 
CONH-C§-). 3.38 (m. lH, CONH-CH2-):3".53 (d. 
2H. Ph-C~-N). 3.86 (d. 2H. Ph--CH2-N). 3.97 (t. lH, 
10 CH.--OH). 4.3S (t. lH. CH2-0.H..). S.43 (d. lH. 
CH-OH). 7.22 (m. 15H. aromatic H), 7.80 (t. lH. CON 
!!..); FABMS (calculated for C28H35N20 3• 447.2648) m/e 
447.2640 (M++l). A solution of S.52 g (11 rnmol) of 41 in 10 mL of 
concentrated HCl was stirred at room temperature for 1 hour. 
Excess HCl was removed under reduced pressure and the 
15 
residue was dried in vacuo overnight to give a brown solid 
N-(2-Phenylethyl)-3-amino-2.S-dihydroxypentamide 
(44) 
of 3-(N.N-dibenzylarnino )-2.5-dihydroxypentanoic acid: 
FABMS (calculated for C1~23N04, 329) m/e 330 (M++l). To a solution of 4.71 g (11 mmol) of 42 (enantiomeric 
This crude product was dissolved in 15 mL of DMF. Upon mixture) in 30 mL of methanol. 1.25 g of 20% Pd(OH)i in 
stirring the solution in an ice bath. 1.30 g (13 mmol) of SO mL of methanol was added. The mixture was hydroge-
triethylamine was added and the mixture was stirred for 10 20 nated at room temperature for 22 hours and then filtered 
minutes. To this mixture was sequentially added 1.62 g (12 through two layers of filter paper. Methanol was removed 
mmol) of HOBt in S mL of DMF. 2.00 g (16 mmol) of from the filtrate with a rotary evaporator. The residue was 
phenethylamine.2.72 g (13 mmol) of DCC in 5 mLofDMF. dried in vacuo ovemightto give 2.74 g (11mmol,100%) of 
The resulting solution was stirred at 10° C. for 72 hours. The a white solid ( enantiomeric ratio=3: 1 ): 1 H NMR (DMS0-«4) 
mixture was heated until the solids dissolved (approximately 25 ol.36 (m, 2H. J3----CH2). 2.71 (m. 2H. C--C!!2-Ph). 2.95 
at 85° C.) and allowed to stand 10° C. overnight. The (dt, lH, cc-CH), 3.34 (m. 8H. CH2--0H. CONH--C 
mixture was then filtered to remove DCU. Solvent was H2-· CH_--OH. CH2-0H. -N!!i). 3.67 (d. 0.33H. 
removed from the filtrate under reduced pressure. Ethyl CH-OH.), 3.74 (d. 0.66H. CH--0!!), 7.25 (m. SH. aro-
acetate (200 mL) was added to the residue and the solution matic H). 7.78 (t, lH, CONJ!); FABMS (calculated for 
was sequentially washed with 10% N3iC03 (2-100 mL). 3° C13H21N203. 2S3.1S52) m/e 2S3.1S48 (~+1). 
distilled water (100 mL), and saturated NaCl (100 mL). 
After drying over MgS04 • the solution was filtered and ethyl 
acetate was removed from the filtrate with a rotary evapo-
N-(3-Phenylpropyl)-3-amino-2.5-
dihydroxypentamide (45) 
rator. The crude residue was purified by gel chromatography This was prepared in a manner identical to that for 44, 
(Et0Ac:hexane=4:1) to give two enantiomers; first enanti- 35 except using 4.70 g (10 mmol) of 43 (enantiomeric mixture) 
omer (2.63 g, 6.8 mmol, SS% yield. a yellow hygroscopic to give 2.80 g (10 mmol. 100%) of a white solid 
solid): RrQ.43 (Et0Ac:hexane=4:1); 1H NMR (DMSO-d6) (enantiomeric ratio=2:1): 1H NMR (DMSO-~) ol.43 (m. 
ol.33 (m, lH. [3---CH). 1.86 (m. lH. 13----CH), 2.69 (t, 2H, 2H. 4-CH 2), 1.69 (m. 2H, CONH-CH2-C 
CH2-Ph), 2.97 (m. lH. cc-CH), 3.23 (m. 4H, c 40 H2-CH2-Ph), 2.52 (m. 3H, C--CH2-Ph, a-CH), 3.06 
H2--0H, CONH--C!!2-), 3.SO (d, 2H. Ph--CH2-N), (m, SH, CH -OH. CONH--C~--:CH..- OH). 3.49 (m. 
3.81 (d. 2H. Ph--CHr-N). 4.26 (t, lH. CH2--0H..). 436 lH. CH2~H.). 3.53 (br. 2H, -~). 3.69 (d. 0.33H. d. (d, rn. CH..--OH). 5.66 (d. lH, CH-OH_). 7.23 (m. lSH, CH--0!!). 3.78 (d. 0.66H. CH--0!!), 7.21 (m. SH, aro-
aromatic H), 7.85 (t, lH, CONH.); FABMS (calculated for matic H), 7.84 (t, lH, t, CON!!). FABMS (calculated for 
C27H33N20 3, 433) m/e 433 ~+l). Second enantiomer 45 C14H23N20 3• 267.1709) m/e 267.1699 (~+l). (0.87 g. 2.0 mmol. 18% yield. a yellow oil): R_,=0.21 
(Et0Ac:hexane=4:1); 1H NMR (DMSO-~) ol.72 (m. 2H. N-(2-Phenylethyl)-3-(N-
[3---CH), 2.73 (t, 2H. C-CH2-Ph), 2.99 (q. lH. cc-CH). benzyloxycarbonylalanylamino)-2.5-
3.32 (m, 4H, CH2--0H. cY>NH--CH2-). 3.52 (d. 2H. dihydroxypentamide (46) 
Ph~-N). 3.82 (d, 2H. Ph--C§-N), 3.9s (t, lH, 50 Upon stirring a solution of 2.71 g (10.74 mmol) of 44 
CH2--0H..). 43S (d, lH, CH_--OH), s.49 (d, lH. CH--0 (mixture of enantiomers) in 10 mL of DMF in an ice bath, 
HJ, 7.22 (m, 15H, aromatic H), 7.82 (t, lH, CON!!.); 1.o8 g (8 mmol) of HOBt and 2.00 g (8.95 mmol) of 
FABMS (calculated for C27H33N 203.433) m/e 433 (M+ + 1 ). N-benzyloxycarbonylalanine in 10 mL of DMF. and 2.21 g 
N-(3-Phenylpropyl)-3-(N,N-dibenzylamino)-2,5-
dihydroxypentamide (43) 
(10.74 mmol) of DCC in 10 mL of DMF were added 
55 sequentially. The mixture was stirred at 10° C. for 24 hours. 
The mixture was heated until the solids dissolved (90° C. ). 
This was prepared in a manner identical to that for 42, The solution was stood at 10° C. overnight and filtered to 
except using 3-phenyl-1-propylamine. 3.97 g (0.019 mole) remove DCU. Solvent was removed from the filtrate under 
instead of phenethylamine to give two enantiomers; first reduced pressure. Ethyl acetate (100 mL) was added to the 
enantiomer (3.40 g. 7 .6 rnmol, 47% yield, a yellow hygro- 60 residue and the solution was washed with saturated NaHC03 
scopic solid): Rj=0.30 (Et0Ac:hexane=4:1); 1H NMR (50 mL). lM HCl (50 mL) and distilled water (50 mL). 
(DMSO-~) ol.39 (m. lH. ~H). 1.68 (p, 2H, CONH- Methanol (20 mL) and MgS04 were added to the final 
CH2-CH2-CH2-Ph), 1.88 (m. lH, 13----CH). 2.S2 (t, 2H, solution, which was allowed to stand at room temperature 
C--CH2 Ph). 2.97 (d, lH. cc-CH), 3.07 (q, 2H, C overnight, and filtered. Solvent was removed from the 
H2--0H). 3.19 (m. lH. CONH--CH2-), 3.SS (m. 3H. 65 filtrate with a rotary evaporator and the residue was recrys-
Ph--C§-N. CONH-CH2-). 3.81 (d. 2H, Ph--C tallized from Et0Ac:methanol:hexane=2:0.S:l to give 2.82 
H2-N), 4.26 (t. lH, CH2--0H ). 4.36 (d, lH, C g (6.16 mmol. 68%) of a white solid <Rr0.34. 0.27. 
5,763.576 
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5-CH2). 3.86 (m. 2H, Ala. Val a-CH). 4.10 (m. lH. 
penta'iiiide 3-CH). 4.28 (m. 2H. pentamide 2-CH. 
S-CH2-0H ), 5.00. (s. 2H. PhC!!10CONH). 5.73 (d. lH. 
pentamide 2-CH-Oll..). 7.24 (m. llH. aromatic CH's, 
EtOAc:MeOH=lO:l. enantiomer ratio=3.8:1.0): mp 
142°-144° C.; 1H NMR (DMSO-d6) ol.18 (d, 3H. Ala 13--C 
H3). 1.44 (m. 2H. pentamide 4-CH2). 2.72 (t, 2H. C-C 
H2-Ph), 3.31 (m. 4H. C!!1--0H.CONH-CH2-). 3.87 
(dd. lH. pentamide 3-CID. 4.08 (m. 2H. Ala a-CH... 
pentamide 2-CH.). 4.27 (t. lH. CH2-0ll..). 5.01(dd.2H. 
Ph-CH2-0CO). 5.77 (d. 0.79H. CH-OH). 5.86 (d, 
0.21H. CH-OH..). 7.26 (m. lOH. aromatic H). 7.41 (d. lH. 
CONll..). 7.57 (cl lH. CONH ). 7.84 (t. lH. CONll..); 
FABMS (calculated for C24H32N30 6. 458.2291) m/e 10 
458.2325 (W+l). 
5 Ala-NH). 7.62 (d. lH. PhCH20CONll..). 7.83 (t. lH. CON 
ll..-CH2-CH2Ph). 7.97 (d, lH, Val-NH); FABMS 
(calculated for C30H43N40 7 • 571.3132) m/e 5571.3169 
(W+l). 
N-(3-Phenylpropyl)-3-(N-
benzyloxycarbonylalanylamino )-2.5-
dihydroxypentamide (47) 
N-(2-Phenylethyl)-3-(N-
benzyloxycarbony lalany lamino )-5-t-
butyldimethylsilyloxy-2-hydroxypentamide (50) 
Upon stirring a solution of 46 ( 1.13 g. 2.5 mmol) in 7 rnL 
of DMF. t-butyldimethylsilyl chloride (0.745 g. 3.0 mmol) 
15 and imidazole (0.37 g. 5.5 mmol) were added sequentially. 
This was prepared in a manner identical to that for 46, The resulting mixture was stirred at room temperature for 4 7 
except using 2.00 g (7 .5 mmol) of 45 ( enantiomeric mixture) hours. Saturated NH4Cl solution (20 mL) was added and the 
to give 1.62 g (3.4 mmol. 45%) of a white solid (enantiomer mixture stirred at room temperature for 5 minutes and was 
rati0=3:1): R_,=0.09 (EtOAc); mp 109°-119° C.; 1H NMR extracted with EtOAc (4><25 mL). The combined extracts 
(DMSO-~) ol.18 (d, 3H. Ala 13--CH3), 1.50 (m. 2H, 20 were dried over MgS04 and filtered. Solvent was removed 
pentamide 4-CH2). 1.70 (p. 2H. CH2-CH2-CHzPh). from the filtrate with a rotary evaporator and the crude 2.54 (t. 2H. CH2-CH2-CH2Ph). 3.09 (m-:-2a. N-C product was purified by gel chromatography (EtOAc) to !!1-CH2- CH2Ph). 3.31(m.2H. pentamide 5-CHz). 3.88 give 0.80 g (1.40 mmole. 56%) of a white solid (enatiomeric (m. 1H. Ala a-CHJ. 4.08 (m, 2H. pentamide 2-CH, rati0=3.2:1): R;=0.51, 0.41(EtOAc); 1H NMR (DMSO-~) 
3-CH) 4 30 (t lH t 'd 5-CH -OH.) 5 01 (dcl 25 80.02 (s. 6H. Si-C~'s). 0.84 (s, 9H. Si-t-Bu). 1.20 (d, 
· • · • · pen amt e 2 · · 3H, Ala 13--CH3). 1.52 (m. 2H. pentamide 4-C&2. 2.72 (t, 2H. Ph-CH2-0CO). 5.73, 5.81 (d, 0.75H, pentamide 2H, C-C
51
H =l>h). 3.38 (m. 4H, CH2-0H, CONH-C 2-CH--OHJ. 5.81 (d, 0.25H. pentamide 2-CH-OH ). r<tT"\ 
7.31 (m. llH. aromatic CH's. CONH..-Ala). 7.57 (d, lH. .!!.-), 3.8 dd, lH. pentamide 3~"-'· 4.07 (m. 2H.Ala 
Oc 8 1 CON 
a-H • pentamide 2-CH..). 5.00 (s. 2H, Ph-C 
PhCH2 ONll..). 7. 5 (t. H. 30 H2-0CO). 5.75 (d. 0.76H. pentamide 2-CH--OH.). 5.86 H..CH2-CH2-CHzPh); FABMS (calculated for fc[ 0.24H. pentamide 2-CH-OH). 7.31 (m. UH. aromatic 
C25H34N306. 472.2448) m/e 472.2411 (M++l). H. CONll.), 7.45 (d, lH. CONH..). 7.74 (t, lH, t, CON 
N-(2-Phenylethyl)-3-(N-
benzyloxycarbonylvalylalanylamino )-2,5-
dihydroxypentamide ( 48) 
This was prepared in a manner identical to that for 46, 
except using 1.28 g (4.0-mmol) of Cbz-Val-Ala-OH to 
35 
!l); FABMS (calculated for C3off46N30 6Si. 572.3156) m/e 
572.3151 (W+l). 
N-(3-Phenylpropyl)-3-(N-
benzyloxycarbonylalanylamino )-5-t-
butyldimethylsilyloxy-2-hydroxypentamide (51) 
give 0.92 g (1.1mmol.44%) of a white solid (enantiomeric This was prepared in a manner identical to that for 50. 
ratio could not be determined due to the overlap of the 40 except using 1.59 g (3.4 mmol) of 47 to give 1.56 g (2.6 
pentamide 2-CH-OH.. peaks in the 1H MNR spectrum): mmol. 78%) of a colorless oil (enantiomeric ratio=2.2:1): 
mp 218°-220° C.; 1H NMR (DMSO-~) 00.82 (dcl 6H. Val ~0.43, 0.38 (EtOAc); 1H NMR (DMSO-~) ~0.03 (s. 6H, 
13--CH3's), 1.17 (d. 3H. Ala 13--CH3). 1.43 (m. 2H. penta- S1-CH3's). 0.78 (s. 9H. Si-t-Bu). 1.17 (d. 3H. Ala 13--C 
mide 4-C!!.). 1.95 (m. lH. Val 13--CH), 2.71 (t. 2H. H3). 130 (m. 2H. pentamide 4-C§). 1.69 (m. 2H, 
CONH-CH2-C!!.Ph). 3.29 (m. 4H, pentamide 5-CH2• 45 CDNHCH2-9.!a-CHzPh). 2.53 (t, 2H. CONHCH2-
N-CH2-CH2Ph), 3.85 (m. 2H.Ala. Val a-CH), 4.08 (m. CH2-C!!a_-Ph). 3.10 (m. 4H, CH2--0H. CONH-C 
lH. pentamide 3-CH), 4.26 (m. 2H, pentamide 2-CH. !!1-). 3.85 (dcL lH. pentamide 3-CH), 4.07 (m. 2H. Ala 
13--CH2--0li.). 5.01 (s. 2H. PhC§OCONH), 5.76 (d. lH. a-CH_, pentamide 2-CH..), ?·OO (s. 2H. Ph-C 
pentamide 2-CH-OHJ 7.29 (m. UH aromatic CH's H2--0CO), 5.73 (d, 0.8H, pentamide 2-CH--OH..). 5.82 
Ala-NH). 7.61 (d. lH. PhCH20CONll..). 7.82 (t. lH. CON 50 ~ OC.20~)ntami7 5'5de(~~H-OCONHHJ\7.i88(6m.( 11rH· aromaco~ 
H_-CH2-CH2Ph), 7.95 (d. lH. Val-NH); FABMS • - • · • • !:.!..I• • • t. • t. l~~culated for C2JI41N40 7 , 557.2975) m/e 557.2935 (W+ ~8g_jfs1!~~i:i~~ulated for C31H48N30 6S1, 586.3312) m/e 
N-(3-Phenylpropyl)-3-(N-
benzyloxycarbonylvalylalanylamino )-2.5-
dihydroxypentamide (49) 
55 
N-(2-Phenylethyl)-3-(N-
benzyloxycarbonylvalylalanylamino)-5-t-
butyldimethylsilyloxy-2-hydroxypentamide (52) 
This was prepared in a manner identical to that for 50, 
This was prepared in a manner identical to that for 46, except using 0.63 g (1.1 mmol) of 48 to give 0.54 g (0.8 
exceptusing2.98g(9.2mmol)ofCbz-Val-Ala-OHand mmol, 71%) of a solid (enatiomeric ratio was not 
2.71 g (10.17 mmol) of 45 to give 2.37 g (4.15 mmol, 44%) 60 determined): ~· 0.27 <,EtOAc); 1H NMR. (DMSO-d6) 
of a white solid (enantiomeric ratio could not be 1:: "04 ( 6H -CH ) o 83 ( 15H s B "-' 1 U-V, S, , 1 J S , • ffi. , 1-t- U, YiU 
determined): R_,=0.07 (EtOAc); mp 192°-193° C.; H NMR 13--CH3's). 1.18 (d, 31[" Ala 13--'-CH ), 1.50 (m. 2H, penta-(DMSO-~) 00.82 (dd. 6H. Val 13--CH3's), 1.17 (d. 3H, Ala mide 4-CH2). 1.95 (m. lH. V~H), 2.72 (t, 2H, 
13--CH3), 1.50 (m. 2H. pentamide 4-CH2), 1.70 (m. 2H. CONHCH2.::::C§Ph), 3.28 (m. 2H, CONHC!!i-CHzPh), 
CONH-CH2-CH2-CH2Ph). 1.94 (m. lH, Val J>-CH). 65 3.48 (m. 2H, pentamide 5-CH2--0H). 3.87 (m. 2H, Ala. 
2.53 (t. 2H. CONH-CH2-CH2-CH2Ph), 3.07 (m. 2H, Val a-CH..). 4.12 (m. lH. pentamide 3-CH...), 432 (m. 
CONH-CH2-CH2-CH2Ph), 3.32 Tm. 2H. pentamide lH. pentamide 2-Cli), 5.01 (s. 2H, Ph-CH2-0CO), 5.74 
5,763,576 
41 
( d. lH, pentamide 2-CH-0!!). 7 .25 (m, UH. aromatic H. 
CONH..). 7.62 (d, lH. CONH ). 7.82 (t, lH. CON!L). 7.93 
(d, lH. CON!L); FABMS (calculated for C35H55N40 7Si, 
671.3840) m/e 671.3895 (W+l). 
5 
no. 
N-(3-Phenylpropyl)-3-(N-
benzyloxycarbonyl valylalanylamino )-5-t-
butyldimethylsilyloxy-2-hydroxypentamide ( 53) 
This was prepared in a manner identical to that for 50. 10 
except using 1.00 g (1.7 mmol) of 49 to give 1.01 g (1.4 
mmol. 84%) of a solid (enatiomeric ratio was not 
determined): Rr=0.42. 0.30 (EtOAc); 1H NMR (DMSO-d6) 
&--0.05 (s, 6H. Si-CH3's). 0.81 (m. 15H. Si-t-Bu. Val 
j3-CH3's). 1.17 (d. 3H. Ala j3-CH3). 1.57 (m. 2H. penta- 15 
mide 4-CH2). 1.70 (m. 2H, CONHCH2-CH2-CH:J>h), 
1.95 (m. Ilf. Val 13---CH). 2.53 (t. 2H. ct>NHCH2-
CH2-CHiPb). 3.10 (m, 2H. CONHCH2-CH2-CHiPb). 
3.51 (m.2H. pentamide 5-CH2-0H):-3.87 (m, 2H. Ala, 
Val a-CH_), 4.12 (m, lH. pentamide 3-CH..). 432 (m. 20 
lH. pentamide 2-CH ). 5.01 (s. 2H. Ph-CH2-0CO), 
5.73 (d. lH, pentamide 2-CH-O!!.). 7.25 (m711H, aro-
matic H. CONH ). 7.65 (d. lH. CON!L), 7.80 (t, lH, CON 
!!), 7.93 (d, lH. CON!L); FABMS (calculated for 
C36H57N40 7Si, 685.0) m/e 685.3 (W+l). 25 
General Procedure for Compounds 54-57 (Cbz-
Ala-Asp-CONH-CH2CH2Ph. 54) 
Upon stirring a solution of 50 (1.10 g. 1.9 mmol) in 30 
CH2Cl2 (6 mL) and E~O (2 mL) with cooling (ice bath), 
chromium trioxide (0.38 g. 3.8 mmol) was added and the 
mixture was stirred at 5° C. under an argon atmosphere for 
2 hours. The solvent was removed from the mixture under 
reduced pressure. Acetic acid (7 mL). H20 (0.8 mL), and 35 
Cr03 (0.77 g, 7.6 mmol) were added and the mixture was 
stirred at room temperature for 3 hours. The resulting 
mixture was diluted with EtOAdisopropanol (10:1. 100 
mL). dried over MgS04 , and filtered through silica gel. The 
solvent was removed from the filtrate and the crude product 40 
was purified by gel column chromatography (EtOAc) to give 
0.16 g (0.34 mmol, 17% yield) of a colorless oil (Rr0.54. 
EtOAc). 
TABLE IV 
Physical properties of g-Keto Amides. 
FABMS m/e (M+ + l) 
no. mp (°C.) Formula Calculated FoUDd Anal. 
50 
65--07 C10H24N206 365.1713 365.1738 C,H,N 
116-117 C 1~206 379.1869 379.1860 C,H,N 
135-137 C 1.,H~206 373.1399 373.1368 C,H,N 
128-129 C21H,,N20 6 399.1556 399.1579 C,H,N 
nd C13H17N20.Cl 265.1188 265.1178* C,H,N 
12 
13 
15 
24 
25 
26 
27 
28 
29 
31 
33 
35 
12 
13 
14 
15 
24 
25 
26 
27 
28 
29 
31 
33 
35 
36 
54 
55 
56 
57 
nd C14H,,,N20.c1 279.1345 279.1372* C,H,N 55 36 
181-182 C 20H22N20 6S 419.1277 419.1263 C,H,N 
120-121 C,.,H27N30 6 406.1978 406.1993 C,H,N 
147-149 c,,.H:wN.o, 539.2506 539.2487 C,H,N 
160-162 C,.,H~407 553.2662 553.2659 C,H,N 
215-216 CwH38N40 7 567.2819 567.2845 C,H,N 
198-199 CwH37N40,,Cl 601.2429 601.2465 C,H,N 
140-142 C32H41N50 9 640.~2 640.2963 C,H,N 60 54 
161-163 C33H.,N50 9 654.3139 654.3110 C,H,N 
nd C24H,7N30 7 470.1927 479.1936 C,H,N 
nd C25H,,,N30 7 484.2084 484.2154 C,H,N 
135-137 C~N408 569.2611 569.2634 C,H,N 
nd CwH •• N.o. 583.2768 583.2781 C,H,N 55• 
~~~~~~~~~~~~~~~~~~~~- 65 
*[M+H-HCW 
42 
TABLE V 
Proton NMR Data IDMSO-d6) for Selected Compounds. 
major signals 
l.42(s, 9H, Boe CH,'s), 2.74(t, 2H, CH2Ph), 2.95(obs, 2H, 
~-CH,), 3.30(m, 2H, NHQ!,), 4.82(m, IH, o:-CH), 7.24(m, 
SH, aromatic CH's), 8.65(br;1H, COOH). 
1.38(s, 9H, Boe CH,'s), l.67(t, 2H, CH£!!,CH2Ph), 2.57(obs, 
2H, CH2Ph), 2.6l(m, IH, I of ~-CH,), 3.11\m, 3H, NHQ!, & I 
of ~-CH,), 4.26(m, lH, o:-CH), 7.0l(d, lH, urethane NH), 7.21(m, 
5H, aromatic CH's), 7.85(br, IH, amide NH), 8.80(br, IH, 
COOH). 
2.68(m, 4H, P-CH,, CH2CfuPh), 3.3l(m. 2H, CONHC!!,CH2), 
5.0l(m, 3H, o:-CH,, PhC!!,OCO), 7 .25(m. lOIL aromatic-ff), 7 .75 
(d, IH, OCONH), 8.78(t, llI, keto amide NH), l 2.46(br, lH, 
COOH). 
2.73(1, 2H, CH2Ph), 3.37(m, 4H, NHQ!, & ~-CH,), 3.97(m, lH, 
ex-CH), 7.24(m, 5H, aromatic CH's), 8.61(br, 3H, NH3 +), 8.75(1, 
IH, amide NH). 
l.72(m, 2H, CH£!!,CH,Ph), 2.58(t, 2H, CH,Ph), 2.80(ABX, 2H, 
~-CH,), 3.09(m, 2H,°MIQ!,), 4.00(m, IH, o:-CH), 7 .22(m, 5H, 
aromatic CH's), 8.57 (br, 31£; NH3 +), 8.79(br, IH, amide NH). 
2.67(m, 4H, CH2Ph & ~-CH,), 3.25(q, 2H, NHQ!,), 4.60(q, lH, 
o:-CH), 5.08(s, 2H, benzyl CH,), 7 .3l(m, !OH, aromatic CH's), 
7.97(br, IH, amide NH), 8.17(d, lH, sulfonamide NH), 8.75(br, 
IH, COOH). 
0.84(d, 6H, (C!!,),CHCH2CO, 1.93(m, 3H, (CH3),C!!CH2CO, 
PhC!!,CH:zNHCl:I), 2.73(m, 4H, Asp ~-CH,, PhCH£!!,NHCO), 
3.15(cl; 2H, (CH3 ),CHC!!,CO, 3.69(d, 2H, Gly o:-CH2),-5.06(br, 
lH, Asp o:-CH), 7 .20(m, aromatic CH's), 7.99(1, IH, 
(CH3),CHCH2CON!!), 8.22(br, IH, Gly amide NH), 8.66(br, IH, 
cx-keto amide NH). 
1.14(m, 6H, 2 Ala CH,'s), 2.44(m, 6H, PhCfuCH,CO, 
PhC!!,CH,NHCO, Asp ~H,'s), 3.27(m, 5H;PhCH,CfuCO, 
PhCJi,CfuNHCO, COOH), 4.26(m, 2H, Ala o:-CH), 5.00(br, 
IH, Asp o::CH), 7 .20(m, lOH, aromatic CH's), 8.03(m, 3H, Ala, 
Asp amide NH's), 8.63(br, lH, cx-keto amide NH). 
0.80(m, 6H, Val CH,'s), 1.91(m, lH, Val ~H), 2.40(m, 4H, 
PhC!!,CH2CONH, COCONHCH2C!!,Ph), 2.77(m, 6H, Asp 
~-CH;'s, PhCH2CfuCONH, COCONJfQ!,CH2Ph), 3.72(m, 2H, 
Gly o:-CH,), 4.09(ni; lH, Val o:-CH), 5.15(br, lH, Asp o:-CH), 
7.2l(m, aromatic CH's), 793(m, 3H, Val, Gly, Asp amide NH), 
8.7l(br, lH, ix-keto amide NH), 12.38(br, lH, COOH). 
0.75(m, 6H, Val CH,'s), l.16(m, 3H, Ala CH3 ), 1.9l(m, IH, Val 
~H). 2.45(m, 4H, Asp ~-CH,'s, PhC!!,CH,CO), 2.76(m, 6H, 
PhCH2CH2NHCO, PhQhCH2CO), 4.14(t, lH, Val o:-CH), 4.28(t, 
lH, ATa o::CH), 5.03, (br,-lH, Asp o:-CH), 7.20(m, lOH, aromatic 
CH's), 7.85(d, lH, Val amide NH), 8.CXl(d, lH, Ala amide NH), 
8.26(br, lH, Asp amide NH), 8.68(br, lH, o:-keto amide NH), 
12.42(br, lH, COOH). 
0.74(m, 6H, Val CH,'s), 1.16(m, 3H, Ala CH3 ), 1.89(m, IH, Val 
~-CH), 2.43(m, 4H, Asp ~-CH,'s, PhCH£!!,CO), 2.72(m, 6H, 
PhC_!!,Q!,NHCO, PhC_!!,CH,CO), 4.13(1, IR, Val o:-CH), 4.28 
(t, 1H,-Ala o:-CH), 5.04,(Dr, IH, Asp o:-CH), 7.2fl, (m, 9H, 
aromatic CH's), 7.86(d, lH, Val amide NH), 8.00(d, IH, Ala 
amide NH), 8.26(br, lH, Asp amide NH), 8.69(br, lH, o:-keto 
amide NH), 12.48(br, lH, COOH). 
0.76(m, 6H, Val CH,'s), 1.19(d, 3H, Ala CH3 ), 1.75(s, 3H, Ac 
CH3), 1.94(m, lH, Val ~-CH), 2.68(m, 6H, CH2Ph, Asp & 'fyr 
~H,'s), 3.26(q, 2H, NHQ!,), 4.19 & 4.48(m, 4H, o:-CH's), 
6.62 & 7.02(2xd, 4H, 'fyr arcinatic CH's), 7.2l(m, 5H, phenyl 
aromatic CH's), 7 .75(t, lH, amide NH), 7 .84(d, lH, amide NH), 
7.92(d, IH, amide NH), 8.07(m, 2H, amide NH's), 9.15(br, lH, 
'fyr OH). 
0.77(2xd, 6H, Val CH,'s), l.21(d, 3H, Ala CH.), 1.66(m, 2H, 
CH.Q!!,CH,Ph), 1.75(s, 3H, Ac CH.), 1.95(m, IH, Val ~-CH). 
2.70(m, -6H, CH,Ph, Asp & 'fyr ~-CH,'s), 3.05(app q, 2H 
NHQ!,), 4.20 & 4.48(m, 4H, o:-CH's), 6.63 & 7.02(2xd, 4H, 'fyr 
aromatii: CH's), 7.25 (m, 5H, phenyl aromatic CH's), 7.83 & 8.08 
(m, SH, amide NH's), 9.18(br, lH, 'fyr OH), 11.06(br, III, 
COOH). 
1.22(d, 3H, Ala CH,), 2,75(!, 2H, C--C!!,-Ph), 2.99(1, 2H, Asp 
~-CH,), 3.34(m, 2H, CONH--C!!,-CH,Ph), 4.32(m, 3H, Ala 
o:-CH, PhCH20CON!!, Asp o:-CH), 5.00(s, 2H, 
P~-OCO), 7.28(m, lOH, aromatic H), 7 .66(d, lH, Asp 
amide NH), 8,99(!, lH, keto amide N!!), 10.89(s, lH, COOH). 
1.38(d, 3H, Ala CH3), l.87(m, 2H, CONHCH2--C!!,--CH2Ph), 
2.64(1, 2H, C--C!!,i'aPh), 3.12(m, 2H, Asp P-CH,), 3.33(m, 2H, 
CONH--C!4--Clf,Ph), 4.52(m, 3H, Ala o:-CH, CONH, 
5,763,576 
43 44 
TABLE V-continued TABLE V-continued 
Proton NMR Data IDMSO-d6l fur Selected Compounds. Proton NMR Data (DMS0-06) for Selected Compounds. 
oo. major signals 5 
no. major signals 
56* 
57 
Asp ex-CH), 5.09(dd, 2H, Ph--q!,-OCO), 5.78(d, lH, 
PHCH20CON!!), 7.32(m, llH, aromatic H, keto amide N!!), 
9.66(s, lH, COOH). 
0.93(dd, 6H, Val CH,'s), 1.36(d, 3H, Ala CH3), 2.09(m, lH, Val 
p-CH), 2,84(t, 2H, CONHCH2-C!!,Ph), 3.15(m, 2H, Asp 
P..cH2), 3.56(dd, 2H, CONHC!!,-Ol,Ph), 4.08(m, lH, Ala 
ex-CH), 4.5l(m, lH, Val ex-CH), 4.70(m, lH, Asp ex-CH), 5.11 
(s, 2H, PhC!!,OCO), 5.75(d, lH, PhCH20CON!!), 7.26(m, 13H, 
aromatic CH's, Ala, Asp, amide NH's, ex-keto amide NH), 9.75(s, 
lH, COOH). 
0.84(dd, 6H, Val CH,'s), 1.24(m, 3H, Ala CH,), 1.74(p, 2H, 
CONHCH2-C!!,-CH2Ph), l.94(m, lH, Val P..cH), 2.55(t, 2H, 
CONHCH,-CH;-C!!zPh), 2.99(t, 2H, 
CONHC!!z-CH,-eH;Ph), 3.12(dd, 2H, Asp P-CH,), 
3.88(m, U{, Ala ex-CH), 4.41(m, 3H, Asp ex-CH, PhCH20CON!!;, 
10 
15 
Val ex-CH), 5.0l(s, 2H, PhCH,-OCO), 7.28(m, UH, aromatic 
CH's, Val amide NH), 8.24(d, lH, Ala amide NH), 8.96(t, lH, 
ex-keto amide NH), 10.85(br, lH, COOH). 
•Data obtained in CDC!,. 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 
and their equivalents. 
SEQUENCE LISTINO 
( I ) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 8 
( 2 ) INFORMATION FOR SEQ ID NO:I: 
( i ) SEQUENCE CHARACI'ERISTICS: 
( A ) LENGTH: 4 amino acids 
( B ) TYPE: amino acid 
( D ) 10POLOOY: linear 
i i ) MOLECULE TYPE: peptide 
( i i i ) HYPOTHETICAL: no 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:!: 
Ala Ala Ala Val 
I 
( 2 ) INFORMATION FOR SEQ ID N0:2: 
i ) SEQUENCE CHARACil!RISTICS: 
( A ) LENGTH: 4 amino acids 
( B ) TYPE: amino acid 
( D ) IDPOLOOY: linear 
( i i ) MOLECULE TYPE: peptide 
( i i i ) HYPOllil!TICAL: no 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N0:2: 
Ala Ala Ala Ala 
1 
( 2 ) INFORMATION FOR SEQ ID N0:3: 
( i ) SEQUENCE CHARACil!RISTICS: 
( A ) LENOTH: 4 amino acids 
( B ) TYPE: amino acid 
( D ) 10POLOOY: lincK 
( i i ) MOLECULE TYPE: pcp6de 
i i i ) HYPOllil!TICAL: no 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:J: 
Ala Ala Pro Met 
1 
45 
( 2 ) INFORMIJION FOR SEQ ID N0:4: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LEN01H: 4 amino acids 
( B ) TYPE: amino acid 
( D ) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: peptide 
( i i i ) HYPOTHETICAL: oo 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N0:4: 
Ala Ala Pro Val 
1 
( 2 ) INFORMIJION FOR SEQ ID N0:5: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LEN01H: 4 amino acids 
( B ) TYPE: amino acid 
( D ) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: peptide 
i i i ) HYPOTHETICAL: no 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:S: 
Lys Val Pro Val 
I 
( 2 ) INFORMATION FOR SEQ ID N0:6: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENcnH: 4 amino acids 
( B ) TYPE: amino acid 
( D ) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: peptide 
i i i ) HYPOTHETICAL: oo 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N0:6: 
Ala Ala Pro Leu 
I 
( 2 ) INFORMAI'JON FOR SEQ ID N0:7: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LEN01H: 4 amino acids 
( B ) TYPE: amino acid 
( D ) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: peptide 
( i i i ) HYPOTHETICAL: DO 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:?: 
lie Ala Oly Arg 
1 
( 2 ) INFORMATION FOR SEQ ID N0:8: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENcnH: 4 amino acids 
( B ) TYPE: amino acid 
( D ) TOPOLOGY: linear 
( i ) MOLECULE TYPE: peptide 
5,763,576 
46 
-continued 
5.763,576 
47 48 
-continued 
( i i i ) HYP01HETICAL: oo 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:B: 
Tyr Val Ala Asp 
I 
What is claimed is: 
1. A compound of the formula: 
or a pharmaceutically acceptable salt. wherein 
10 
15 
M1 represents H. NH2-CO-. NH2--CS-. NH2-
S02-. X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N-CS-. X-NH-S02-. X2N-S02-. 20 
X-CO-. X--CS-. X-S02-. X-0-CO-. or 
X-0-CS-; 
x is selected from the group consisting of c,_10 alkyl. 
C,_10 tluoroalkyl. C1_10 alkyl substituted with J. C1_10 
tluoroalkyl substituted with J. 1-admantyl. 9-tluorenyl. 25 
phenyl. phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K. naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K. 
naphthyl trisubstituted with K, c,_10 alkyl with an 
attached phenyl group. c,_10 alkyl with two attached 30 
phenyl groups, c,_,o alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with two attached 
phenyl groups substituted with K, C1_10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 35 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH, CN. N02• NH2• C1_10 alk:oxy, C1_10 alkylamine. 
C2_12 dialkylamine, C1_10 alkyl-0--CO-, C1_10 alkyl-
0--CO-NH-. and C1_10 alkyl-S-; 40 
K is selected from the group consisting of halogen. C1_10 
alkyl. C1_10 pertluoroalkyl. C1_10 alk:oxy. N02• CN. 
OH. C02H. amino. C 1_10 alkylamino. C2_12 
dialkylamino. C1_10 acyl. and C1_10 alk:oxy-CO-. and 
c1_10 alkyl-S-; 45 
AA1.AA2.AA3 andAA4 are the same or <lliferent and are 
side chain blocked or unblocked amino acids with the 
L configuration. D configuration. or no chirality at the 
a-carbon selected from the group consisting of alanine. 
valine, leucine. isoleucine, proline, methionine. 50 
methionine sulfoxide. phenylalanine. tryptophan. 
glycine, serine. threonine. cysteine, tyrosine. 
asparagine, glutamine. aspartic acid, glutamic acid. 
lysine. arginine, histidine, phenylglycine, beta-alanine, 
norleucine. norvaline, alpha-aminobutyric acid, 55 
epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine, homoarginine. sarcosine, indoline 
2-carboxylic acid. 2-azetidinecarboxylic acid, pipe-
c o li nic acid (2-piperidine carboxylic acid), 
0-methylserine, 0-ethylseriQe, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH 2-CH 
(CH2CHEt2 )--COOH. alpha-aminoheptanoic acid. 
NH2-CH(CH2-l-napthyl)-COOH. NH2-CH(CH2-
2-napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-
COOH. NH 2-CH(CH 2-cyclopentyl)-COOH. 
NH 2-CH(CH2 -cyclobutyl)-COOH. NH2-CH 
(CHrcyclopropyl)-COOH, tritluoroleucine. and 
hexatluoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C1_20 alkyl. C3_20 cyclized alkyl. C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl. 
c3-20 cyclized alkyl with an attached phenyl group. 
c3-20 alkyl with an attached phenyl group substituted 
with K. C1_20 alkyl with an attached phenyl group 
disubstituted with K. C1_20 alkyl with an attached 
phenyl group trisubstituted with K, C3_20 cyclized alkyl 
with an attached phenyl group substituted with K. C1_10 
alkyl with a morpholine ring attached through nitrogen 
to the alkyl. C1_10 alkyl with a piperidine ring attached 
through nitrogen to the alkyl. C1_10 alkyl with a pyr-
rolidine ring attached through nitrogen to the alkyl. 
C1_20 alkyl with an OH group attached to the alkyl. 
-CH2CH20CH2CH20H. C1_10 with an attached 
4-pyridyl group. C1_10 with an attached 3-pyridyl 
group. cl-JO with an attached 2-pyridyl group, C1-10 
with an attached cyclohexyl group, -NH-CH2CH2-
( 4-hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 
2. A compound according to claim 1 wherein 
AA 1-AA 2-AA3 -AA 4 is selected from the group con-
sisting of 
(a) AA1-AA2-AA3-Asp and 
(b) AA1-AA2-AA3-Glu. and 
M 1 is selected from the group consisting of X--CO and 
X-0--CO-. and 
R3 is H. 
3. A compound according to claim 1 wherein 
X is selected from the group consisting of C1_10 alkyl. 
phenyl. phenyl substituted with K. C1_10 alkyl with an 
attached phenyl group. C1_10 alkyl with an attached 
phenyl group substituted with K. and 
R4 is selected from the group consisting of C1_20 alkyl 
with a phenyl group attached to the C1_20 alkyl. 
4. A compound or pharmaceutically acceptable salt of the 
compound selected from the group consisting of: 
(a) Ac-Tyr-Val-Ala-Asp-CONH-CH2 CH2Ph 
(SEQ ID N0:8) and 
(b) Ac-Tyr-Val-Ala-Asp-CONH-CH2CH2CHiPb (SEQ ID N0:8). 
* * * * * 
